Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Other Risks and Uncertainties

The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, successful discovery and development of its product candidates, the success of clinical trials and other studies for its product candidates, including for its ongoing V005 Phase II/III clinical trial and V007 Phase III clinical trial, the regulatory approval and commercialization of its HAVs and other product candidates,the expected size of the target populations for the Company’s product candidates, the degree of market acceptance of the HAVs, if approved, the availability of third-party coverage and reimbursement, development by competitors of new technological innovations, the ability to manufacture HAVs and other product candidates in sufficient quantities, expectations regarding the Company’s strategic partnerships, dependence on third parties, key personnel and the ability to attract and retain qualified employees, protection of proprietary technology and confidentiality of trade secrets, compliance with governmental regulations, the impact of the COVID-19 pandemic, the Company’s implementation and maintenance of effective internal controls, and the ability to secure additional capital to fund operations and commercial success of its product candidates.

Product candidates currently under development will require extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities. Even if the Company’s commercialization efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales, and the Company may depend on certain strategic relationships to distribute its products, including the Company’s strategic partnership with Fresenius Medical Care Holdings, Inc., or Fresenius Medical Care, to sell, market and distribute its 6 millimeter HAV for certain specified indications.

Net Loss per Share Attributable to Common Stockholders

The Company follows the two-class method to compute basic and diluted net loss per share attributable to common stockholders when shares met the definition of participating securities. The two-class method determines net loss per common share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods of loss, there is no allocation required under the two-class method since the redeemable convertible preferred stock did not have a contractual obligation to share in the Company’s losses.

Basic net loss per share attributable to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless inclusion of such shares would be anti-dilutive. As the Company has ~~not experienced~~only incurred losses, ~~on this account~~basic and ~~management believes~~diluted net loss per share is the ~~Company is not exposed to significant risks on such account.~~

8same.

Table of Contents

~~Common Stock Subject~~Humacyte,Inc.

Notes to ~~Possible Redemption~~Condensed Consolidated Financial Statements

(unaudited)

The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) are classified as a liability instrument and are measured at fair value. Conditionally redeemable common stock (includingpotential shares of common stock that ~~feature redemption rights that~~were excluded from the computation of diluted net loss per share for each period because including them would have had an antidilutive effect were as follows:


	September 30,
	2021	2020

Shares issuable upon conversion of Series A redeemable convertible preferred stock	—	18,421,897
Shares issuable upon conversion of Series B redeemable convertible preferred stock	—	24,137,647
Shares issuable upon conversion of Series C redeemable convertible preferred stock	—	11,241,283
Shares issuable upon conversion of Series D redeemable convertible preferred stock	—	15,812,735
Exercise of options under stock plan	6,399,888	4,516,907
Warrants to purchase common stock	5,465,204	32,961

The 15,000,000 Contingent Earnout shares are ~~either within~~excluded from the ~~control~~anti-dilutive table for all the periods presented as such shares are contingently issuable until the share price of the ~~holder~~Company exceeds specified thresholds that have not yet been achieved, or ~~subject to redemption~~ upon the occurrence of ~~uncertain~~a change in control.

Impairment of Long-Lived Assets

The Company reviews the carrying value of property and equipment for indicators of possible impairment whenever events and circumstances indicate that the carrying value of an asset or asset group may not ~~solely~~be recoverable from the estimated future net undiscounted cash flows expected to result from its use and eventual disposition. In cases where estimated future net undiscounted cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of the asset or asset group. The factors considered by management in performing this assessment include current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition, and other economic factors. Based on this assessment, during the nine months ended September 30, 2021 and 2020, respectively, the Company concluded there were no such events or changes in circumstances requiring review of the carrying amount of the Company’s long-lived assets and there was 0 impairment at September 30, 2021 or December 31, 2020.

Recently Adopted Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. Either a modified retrospective method of transition or a fully retrospective method of transition is permissible for the adoption of this standard. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, with early adoption permitted. The Company adopted ASU 2020-06 as of January 1, 2021. The adoption of this ASU had no impact on the ~~Company’s control) are~~Company’s financial statements and related disclosures.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Recently Issued Accounting Pronouncements

In May 2021, the FASB issuedASUNo. 2021-04, “Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” (“ASU 2021-04”).The FASB issued this update to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity classified written call options (for example, warrants) that remain equity classified after modification or exchange.ASU2021-04is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the amendments prospectively to modifications or exchanges occurring after the effective date of the amendments. The Company is currently evaluating the effect of this update on its financial statements.

3. Reverse Recapitalization

On August 26, 2021, Merger Sub, a wholly-owned subsidiary of AHAC, merged with Legacy Humacyte, with Legacy Humacyte surviving as ~~temporary equity.~~a wholly-owned subsidiary of AHAC. At ~~all other times, common stock are classified as stockholders’ equity. The~~the effective time of the Merger:

●

each outstanding share of Legacy Humacyte common stock was converted into approximately 0.26260 shares of the Company’s common stock;

●

each outstanding share of preferred stock of Legacy Humacyte was cancelled and converted into the aggregate number of shares of New Humacyte’s common stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.26260; and

●

each outstanding option or warrant to purchase Legacy Humacyte common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company’s common stock equal to the number of shares of Legacy Humacyte common stock subject to such option or warrant multiplied by approximately 0.26260, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.26260;

in each case, rounded down to the nearest whole share.

In addition, upon the closing of the merger (the “Closing”), 2,500,000 Class B shares of AHAC (Founder Shares) automatically converted into shares of the Company’s common stock, ~~feature certain redemption rights that~~on a one-for-one basis.

Former holders of the Legacy Humacyte common stock and Legacy Humacyte preferred stock are ~~considered~~eligible to ~~be outside~~receive up to an aggregate of 15 million additional shares of the Company’s ~~control and subject to the occurrence of uncertain future events. Accordingly, as of September 30, 2020, 9,435,806 shares of Class A~~ common stock ~~subject to possible redemption are presented at redemption value as temporary equity, outside~~(the “Contingent Earnout Shares”) in the aggregate in 2 equal tranches of 7.5 million shares if the volume-weighted average closing sale price of the ~~stockholders’~~common stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period. At the Closing on August 26, 2021, the Company recorded a liability (“Contingent Earnout Liability”) of $159.4 million, based on the estimated fair value of the 15 million Contingent Earnout Shares with a corresponding reduction of additional paid-in capital in the equity section of the Company’s condensed consolidated balance sheet.

Concurrently with the execution of the Business Combination Agreement, AHAC entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “PIPE Investors”). Pursuant to the Subscription Agreements, the PIPE Investors purchased an aggregate of 17,500,000 shares of the Company’s common stock (the “PIPE Shares”) in a private placement at a price of $10.00 per share for an aggregate purchase price of $175 million (the “PIPE Financing”). The PIPE Financing was consummated in connection with the Closing.

Table of Contents

~~Net Income (Loss) per Common Stock~~Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

~~Net loss per common share is computed by dividing net loss by the weighted average~~(unaudited)

The number of ~~common~~ shares ~~outstanding for~~of the ~~period. The Company applies the two-class method in calculating earnings per share. Shares of~~Company’s common stock ~~subject to possible redemption at September 30, 2020, which are not currently redeemable and are not redeemable at fair value, have been excluded from~~outstanding immediately following the ~~calculation of basic net loss per common share since such shares, if redeemed, only participate in their pro rata share~~consummation of the ~~Trust Account earnings. The Company has not considered the effect of warrants sold in the Initial Public Offering and the private placement to purchase an aggregate 5,177,500~~Merger was:


	Shares
Common stock of AHAC, outstanding prior to Merger	10,355,000
Less redemption of AHAC shares	(3,008,551)
Common stock of AHAC	7,346,449
AHAC Founder Shares	2,500,000
New Humacyte shares issued to PIPE Investors	17,500,000
Issuance of common stock upon reverse recapitalization and PIPE Financing	27,346,449
New Humacyte shares issued in Merger to Legacy Humacyte stockholders	75,656,935	(1)
Total shares of common stock immediately after Merger	103,003,384

(1) Includes 69,613,562 shares of common stock issued upon conversion of Legacy Humacyte's redeemable convertible preferred stock.

The Merger is accounted for as a reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, AHAC is treated as the ~~calculation of diluted loss per share, since~~acquired company for financial reporting purposes and Legacy Humacyte is treated as the ~~exercise~~acquiror. This determination is primarily based on the fact that subsequent to the Merger, the Legacy Humacyte stockholders hold a majority of the ~~warrants into~~voting rights of the combined company, Legacy Humacyte comprises all of the ongoing operations of the combined company, Legacy Humacyte comprises a majority of the carryover governing body of the combined company, and Legacy Humacyte’s senior management comprises all of the senior management of the combined company. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Humacyte issuing shares ~~of common stock is contingent upon the occurrence of future events. As a result, diluted net loss per common share is the same as basic net loss per common share~~ for the ~~period presented.~~net assets of AHAC, accompanied by a recapitalization. The net assets of AHAC were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the Merger are those of Legacy Humacyte.

~~Below is a reconciliation of~~In connection with the ~~net loss per common share:~~

For the
three months ended
September 30,
2020
Net loss $ (40,952 )
Add: loss attributable to common stock subject to possible redemption 22,177
Adjusted net loss $ (18,775 )

Weighted average shares outstanding, basic and diluted⁽¹⁾ 2,888,352

Basic and diluted net loss per common share $ (0.01 )

~~(1)~~

~~Calculated from date of issuance (July 1, 2020) through September 30, 2020~~

~~Offering Costs~~

Merger, the Company received $242.4 million in proceeds from the Merger and related PIPE Financing. The Company ~~complies with the requirements~~incurred $3.9 million of ~~the ASC 340-10-S99-1~~transaction costs, consisting of banking, legal, and ~~SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses~~other professional fees, of ~~Offering”. Offering costs consist principally~~which $3.9 million was recorded as a reduction of ~~professional~~proceeds to additional paid-in capital, and ~~registration fees incurred through the balance sheet date that are~~less than $0.1 million related to the Public Offering and that were charged to stockholders’ equity upon the completion of the IPO. Accordingly, on September 22, 2020, offering costs totaling $4,175,978 have been charged to stockholders’ equity (consisting of $2,000,000 of underwriting fee, $1,846,265 of deferred underwriting fee and $329,713 of other offering costs).

~~Fair Value of Financial Instruments~~

~~The fair value of the Company’s assets and~~Private Placement Warrants, which are classified as liabilities ~~which qualify as financial instruments under the Financial Accounting Standards Board (“FASB”) ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented~~ in the condensed consolidated balance ~~sheets.~~sheets, was expensed in the condensed consolidated statements of operations and comprehensive loss. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Of the $15.2 million of liabilities assumed from AHAC, as of September 30, 2021, $2.2 million was included in accounts payable and accrued expenses. In addition, there were $3.0 million of unpaid transaction costs included in accounts payable and accrued expenses as of September 30, 2021.

4. Fair Value Measurements

Fair value is defined as the price that would be received ~~for sale of~~to sell an asset or paid ~~for~~to transfer of a liability in the principal or most advantageous market in an orderly transaction between market participants at the measurement date. ~~GAAP~~ASC 820, Fair Value Measurement and Disclosures, establishes a ~~three-tier fair value~~ hierarchy ~~which prioritizes the~~whereby inputs to valuation techniques used in measuring fair ~~value. The~~value are prioritized, or the fair value hierarchy. There are three levels to the fair value hierarchy ~~gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable~~based on reliability of inputs, ~~(Level 3 measurements). These tiers include:~~

as follows:

●

Level 1 ~~defined as observable~~— Observable inputs ~~such as~~that reflect unadjusted quoted prices ~~(unadjusted)~~ for identical ~~instruments~~assets or liabilities in active ~~markets;~~markets.

●

Level 2 ~~defined as inputs~~— Inputs other than quoted prices included in ~~active markets~~Level 1 that are ~~either directly~~observable for the asset or ~~indirectly observable~~liability, such as quoted prices for similar ~~instruments in active markets~~assets or liabilities, quoted prices ~~for identical or similar instruments~~ in markets that are not ~~active; and~~active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

●

Level 3 ~~defined as unobservable~~— Unobservable inputs in which little or no market data exists, therefore requiring ~~an entity~~the Company to develop its own ~~assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.~~assumptions.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

The ~~following table presents information about~~Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period, utilizing valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The determination requires significant judgments to be made by the Company.

The Company’s assets and liabilities that ~~are~~were measured at fair value on a recurring basis ~~at September 30, 2020~~were as follows:


	Fair Value Measured as of September 30, 2021
($in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	238,375	$	—	$	—	$	238,375
Total financial assets	$	238,375	$	—	$	—	$	238,375
Liabilities:
Contingent earnout liability	$	—	$	—	$	169,200	$	169,200
Common stock warrant liabilities (Private Placement Warrants)		—		—		555		555
Total financial liabilities	$	—	$	—	$	169,755	$	169,755

	Fair Value Measured as of December 31, 2020
($in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	35,623	$	—	$	—	$	35,623
Total financial assets	$	35,623	$	—	$	—	$	35,623

The following table presents a summary of the changes in the fair value of the Company’s Level 3 financial instruments:


	Contingent		Private Placement
($in thousands)	Earnout Liability		Warrants

Fair value as of December 31, 2020	$	—	$	—
Private placement warrant liability acquired as part of the merger		—		(553)
Contingent earount liability recognized upon the closing of the reverse recapitalization		(159,432)		—
Change in fair value included in other (expense) income		(9,768)		(2)
Fair value as of September 30, 2021	$	(169,200)	$	(555)

The fair value of the Contingent Earnout Liability and ~~indicates~~Private Placement Warrants liability are based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy.

In determining the fair value of the Contingent Earnout Liability, the Company used the Monte Carlo simulation value model using a distribution of potential outcomes on a monthly basis over a ten-year period prioritizing the most reliable information available. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Company common stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8).

In determining the fair value of the Private Placement Warrants liability, the Company used the Monte Carlo simulation valuation model to estimate the fair value utilizing assumption including the current Company stock price, expected volatility, risk-free rate, expected term and expected dividend yield (see Note 8).

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

The Company’s cash equivalents are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The carrying values of ~~the valuation inputs the Company utilized to determine such fair value:~~

September 30,
Description Level 2020
Assets:
Marketable securities held in Trust Account 1 $ 99,977,823

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.

~~Income Taxes~~

~~The Company~~other receivables, accounts ~~for income taxes under ASC 740 Income Taxes (“ASC 740”). ASC 740 requires the recognition of deferred tax assets~~payable and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

~~The Company recognizes~~ accrued ~~interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties~~expenses as of September 30, ~~2020.~~2021 and December 31, 2020 approximated their fair values due to the short-term nature of these items.

5. Property and Equipment, Net

Property and equipment, net consist of the following:


	September 30,		December 31,
($ in thousands)	2021		2020

Scientific equipment	$	27,578	$	27,412
Computer equipment		154		149
Software		335		335
Furniture and fixtures		988		988
Leasehold improvements		26,355		26,355
		55,410		55,239
Accumulated depreciation		(18,911)		(14,261)
Property and equipment, net	$	36,499	$	40,978

Depreciation expense totaled $1.5 million and $4.7 million for the three and nine months ended September 30, 2021, respectively, and $1.6 million and $4.7 million for the three and nine months ended September 30, 2020, respectively. All long-lived assets are maintained in the UnitedStates.

6. Accrued Expenses

Accrued expenses consisted of the following:


	September 30,		December 31,
($ in thousands)	2021		2020

Accrued external research, development and manufacturing costs	$	2,685	$	2,615
Accrued employee compensation and benefits		4,025		1,009
Accrued professional fees		2,712		968
Total	$	9,422	$	4,592

7. Debt

On April 30, 2020, the Company received loan proceeds in the amount of approximately $3.3 million under the Paycheck Protection Program (“PPP”). All or portion of this loan and any accrued interest was eligible to be forgiven after a twenty-four week period as long as the borrower used the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of the loan forgiven was to be reduced if the borrower terminated employees or reduced salaries during the twenty-four week period. The unforgiven portion of the PPP loan was to be payable over two years at an interest rate of 1%, with a deferral of payments for the first ten months. On May 25, 2021, the PPP loan was forgiven and the Company recognized a gain from loan extinguishment in the amount of $3,284 during the nine months ended September 30, 2021.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

In March 2021, the Company entered into a term loan agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., which provides a term loan facility of up to $50.0 million with a maturity date of March 1, 2025, or the Loan Agreement. The Company’s obligations under the Loan Agreement are secured by substantially all of its assets except for its intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. If a minimum liquidity amount is not maintained, 50% of the outstanding principal and interest will become cash collateralized. As of September 30, 2021, the Company was in compliance with all covenants. The Company may use the proceeds of borrowings under the Loan Agreement as working capital and to fund its general business requirements.

The Loan Agreement provides that the term loans will be distributed in tranches. The initial term loan tranche of $20.0 million was drawn in March 2021 and is accounted for net of issuance costs which are being accreted to interest expense over the term of the loan using the effective interest method. As of September 30, 2021, 3 subsequent $10.0 million term loan tranches were eligible to be disbursed at the request of the Company during specified draw periods between now and 2023 if certain business development milestones and other specified requirements are met by the dates specified in the Loan Agreement. Borrowings bear interest at the greater of 7.5% or the Wall Street Journal Prime Rate plus 4.25% (7.5% as of September 30, 2021). Interest only payments on the principal amount outstanding are due monthly beginning in the first month after the loan is dispersed. Repayment of principal may begin as soon as April 1, 2022 under the level of borrowing outstanding at September 30, 2021, and no later than April 1, 2024. The term loans may only be prepaid in full, and such prepayment requires 30 days’ advance notice and is subject to a prepayment fee of 3.00% (with a step down to 2.00% after March 30, 2022, and a further step down to 1.00% after March 30, 2023). The Company is ~~currently~~ not ~~aware~~obligated to pay a prepayment fee if the Company makes a prepayment after March 30, 2024.

On October 13, 2021, the Company borrowed an additional $10.0 million under the Loan Agreement. As a result of ~~any issues under review that could result in significant payments, accruals or material deviation from its position.~~the additional borrowing, the commencement of repayment of principal was deferred to no earlier than July 2023.

In connection with the Loan Agreement, the Company granted warrants to the lenders to purchase shares of common stock at an exercise price of $10.28 per share, of which 287,704 warrants were immediately exercisable. The warrants are classified within stockholders’ equity as the settlement of the warrants is indexed to the Company’s own stock. The Company ~~has identified~~recognized the ~~United States~~fair value of the warrants immediately exercisable within stockholders’ equity using a Black-Scholes valuation model at issuance. As of September 30, 2021, the fair value of warrants ($2.4 million), a 5% final payment fee ($1.0 million) and debt issuance costs ($0.3 million) are being accreted to interest expense over the term of the loan using the effective interest method.

At issuance, the Company initially determined that the funding of an additional tranche was not probable, and therefore no value was ascribed to the remaining 123,302 warrants that were only exercisable upon the funding of the additional tranche. As a result of the Company's additional $10.0 million borrowings under the Loan Agreement on October 13, 2021, the warrants to purchase the additional 123,302 shares of the Company's common stock became exercisable at an exercise price of $10.28 per share.

SVB loan payable and net discount or premium balances are as ~~its only “major” tax jurisdiction.~~follows:


	September 30,
($ in thousands)	2021
Principal amount of SVB loan payable	$	20,000
Final payment amount of SVB loan payable		1,000
Net premium associated with accretion of final payment and other debt issuance costs		(3,073)
SVB loan payable, current and noncurrent		17,927
Less SVB loan payable, current portion		(3,889)
SVB loan payable, noncurrent portion	$	14,038

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Future minimum payments of principal on the Company’s outstanding variable rate borrowings as of September 30, 2021 are as follows:


Year ending December 31:	($ in thousands)
2021 (remainder)	$	—
2022		5,555
2023		6,667
2024		6,667
2025		1,111
Total future payments		20,000

8. Stockholders’ Equity (Deficit)

Redeemable Convertible Preferred Stock

As of December 31, 2020 and immediately prior to the Merger, Legacy Humacyte had outstanding series A redeemable convertible preferred stock, series B redeemable convertible preferred stock, series C redeemable convertible preferred stock and series D redeemable convertible preferred stock, which are collectively referred to as “redeemable convertible preferred stock.”

In connection with the Merger, all previously issued and outstanding redeemable convertible preferred stock was converted into an equivalent number of shares of common stock of the Company on a one-to-one basis, then multiplied by the Exchange Ratio pursuant to the Merger Agreement.

Common Stock

On August 26, 2021, the Merger and related PIPE Financing was consummated and the Company issued 27,346,449 shares of common stock for proceeds of $242.4 million. The Company ~~may be subject to potential examination by federal~~incurred $3.9 million of transaction costs, consisting of banking, legal, and ~~state taxing authorities in~~other professional fees. Legacy Humacyte assumed $15.2 million of liabilities, including PIPE Financing fees and legal fees, and $0.1 million of assets from AHAC. Immediately following the ~~areas~~Merger, there were 103,003,384 shares of ~~income taxes. These potential examinations may include questioning~~common stock outstanding with a par value of $0.0001.

As of September 30, 2021, the ~~timing~~Company’s Second Amended and ~~amount~~Restated Certificate of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

~~Recent Accounting Pronouncements~~

~~Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.~~

~~Note 3 — Initial Public Offering~~

~~Pursuant to the IPO on September 22, 2020,~~Incorporation authorized the Company ~~sold 10,000,000 Units, at a purchase price~~to issue 250,000,000 shares of $10.00 per Unit. Each unit that the Company is offering has a price of $10.00 and consists of one share of Class A common stock and one-half of one redeemable warrant. Only whole warrants are exercisable. Each whole warrant entitles the holder to purchase one share of Class A common stock at a ~~price~~par value of ~~$11.50 per share.(see Note 7)~~

~~Note 4 — Private Placement~~

~~Simultaneously with the closing of the IPO, the Company consummated the Private Placement with the Company’s Sponsor~~, AHAC Sponsor LLC, Oppenheimer & Co. Inc. the representative of the underwriter, who is referred to as the representatives and Northland ( purchased an aggregate of 355,000 placement units at a price of $10.00 per unit, for an aggregate purchase price of $3,550,000. Each placement unit is identical to the units sold in the IPO.

The private placement warrants will be non-redeemable and exercisable on a cashless basis so long as they are held by the sponsor, the representative, Northland or their permitted transferees. If the private placement warrants are held by holders other than the sponsor, the representative, Northland or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by the holders on the same basis as the warrants included in the units being sold in the IPO. In addition, for as long as the private placement warrants are held by the representative, Northland or their designees or affiliates, they may not be exercised after five years from the effective date of the registration statement.

The Company’s sponsor, the representative and Northland have agreed to (i) waive their redemption rights with respect to their private placement shares in connection with the completion of the Company’s initial business combination, (ii) waive their redemption rights with respect to their private placement shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to redeem 100% of its public shares if the Company does not complete its initial business combination within 24 months from the closing of the IPO or (B) with respect to any other provision relating to stockholders’ rights or pre-initial business combination activity and (iii) waive their rights to liquidating distributions from the trust account with respect to their private placement shares if the Company fails to complete its initial business combination within 24 months from the closing of the IPO. In addition, the Company’s Sponsor, officers and directors have agreed to vote any founder shares or private placement shares held by them in favor of the Company’s initial business combination.

~~Note 5 — Related Party Transactions~~

~~Founder Shares~~

~~On July 20, 2020, the Company issued 2,875,000 shares of Class B common stock to its initial stockholder, AHAC Sponsor, LLC for $25,000, or approximately $0.01~~$0.0001 per share. The ~~founder shares include an aggregate~~number of ~~up to 375,000 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full.~~

~~As of September 30, 2020, 2,875,000~~authorized shares of common stock ~~(the “Founder Shares”) are issued and outstanding.~~

~~The over-allotment option was~~may be increased or decreased (but not ~~exercised~~below the number of shares thereof then outstanding or reserved for issuance) by the ~~underwriters during the 45-day option period; thus,~~ ~~375,000 shares~~ ~~were forfeited accordingly as of November 1, 2020.~~

~~Promissory Note — Related Party~~

On July 1, 2020, the Company issued an unsecured promissory note to the sponsor, pursuant to which the Company may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the IPO. This loan is non-interest bearing, unsecured, and due on the earlier of (a) March 31, 2021 or (b) the date on which the Company completes the IPO. The loan will be repaid out of the offering proceeds not held in the Trust Account. As of September 30, 2020, the Company had $89,076 in borrowings outstanding under the promissory note.

~~Administrative Service Fee~~

The Company has agreed, commencing on the effective date of the prospectus, to pay an affiliate of the Company’s sponsor a monthly fee of an aggregate of $10,000 for general and administrative services including office space, utilities and secretarial and administrative support. This arrangement will terminate upon completion of a business combination or the liquidation of the Company. For the period July 1, 2020 through September 30, 2020, the Company has accrued $4,334 of administrative fees as a due to related party payable.

~~Related Party Loans~~

In addition, in order to finance transactions costs in connection with a business combination, the sponsor, or certain of the Company’s officers, directors, or their affiliates may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a business combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be converted into units of the post business combination entity at a price of $10.00 per unit.

~~Note 6 — Commitments & Contingencies~~

~~Registration Rights~~

The holders of the founder shares, placement units (including securities contained therein) and units (including securities contained therein) that may be issued upon conversion of working capital loans, and any shares of Class A common stock issuable upon the exercise of the placement warrants and any shares of Class A common stock and warrants (and underlying Class A common stock) that may be issued upon conversion of the units issued as part of the working capital loans and Class A common stock issuable upon conversion of the founder shares, will be entitled to registration rights pursuant to a registration rights agreement to be signed prior to September 22, 2020 the effective date of the IPO, requiring us to register such securities for resale (in the case of the founder shares, only after conversion to our Class A common stock). The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of an initial business combination and rights to require us to register for resale such securities pursuant to Rule 415 under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering our securities. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Notwithstanding the foregoing, the representative and Northland may not exercise their demand and “piggyback” registration rights after five (5) and seven (7) years after the effective date of the registration statement and may not exercise their demand rights on more than one occasion. The Company will bear the expenses incurred in connection with the filing of any such registration statements.

~~Underwriters Agreement~~

The underwriters have a 45-day option beginning September 22, 2020 to purchase up to 1,500,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions.

~~On September 22, 2020, the underwriters were paid an underwriting discount of two percent (2.0%) of the gross proceeds of the IPO, or $2,000,000.~~

In addition, the underwriters are entitled to a deferred underwriting fee of three and a half percent (3.5%) of the gross proceeds of the IPO upon the completion of the Company’s initial business combination. The underwriters have agreed that up to 1% of the deferred underwriting fee may be re-directed to other FINRA member firms that have provided services in connection with the identification and consummation of a business combination, in the sole discretion of the Company; provided, that all such payments to other FINRA member firms may only be made if permitted under applicable law.

The Company may reduce the deferred underwriting fee by up to 50% based on stockholders redeeming their shares for their pro-rata amount of the proceeds in the Trust Account; provided, however, that (a) the underwriters’ maximum deferred underwriting fee reduction based on stockholder redemptions will be 50% regardless of whether stockholder redemptions exceed 50%; and (b) any sums paid to other advisors as discussed above, will be credited against the reduction of and added back to the deferred underwriting fee payable to the underwriters; and (c) under no circumstance will the deferred underwriting fee be less than 1.75% of the gross proceeds of the IPO. ~~As of September 30, 2020, the Company accrued a deferred underwriting fee of $1,846,265 assuming no over-allotment is exercised.~~

~~Note 7 — Stockholder’s Deficit~~

~~Preferred Stock~~ — The Company is authorized to issue a total of 1,000,000 shares of preferred stock at par value of $0.0001 each. At September 30, 2020, there were no shares of preferred stock issued or outstanding.

~~Class A Common Stock~~ ~~— The Company is authorized to issue a total of 100,000,000 shares of Class A common stock at par value of $0.0001 each. At September 30, 2020, there were~~ ~~919,194 shares issued and outstanding (excluding 9,435,806 shares subject to possible redemption)~~

~~Class B Common Stock~~ — The Company is authorized to issue a total of 10,000,000 shares of Class B common stock at par value of $0.0001 each. At September 30, 2020, there were 2,875,000 shares of Class B common stock issued or outstanding. The founder shares include an aggregate of up to 375,000 shares subject to forfeiture if the over-allotment option is not exercised by the underwriters in full. The over-allotment option was not exercised by the underwriters during the 45-day option period; thus, these shares were forfeited accordingly as of November 1, 2020.

~~Both Class A and B stockholders vote together as a single class on all matters submitted to a~~affirmative vote of ~~the Company stockholders, with each share of common stock entitling the holder to one vote.~~

Class B shares are identical to the Class A shares except that Class B shares (founder shares) automatically convert into shares of Class A common stock at the time of the consummation of our initial business combination, on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and subject to further adjustment as provided herein. In the case that additional shares of Class A common stock, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in this prospectus and related to the closing of the initial business combination, the ratio at which shares of Class B common stock shall convert into shares of Class A common stock will be adjusted (unless the holders of a majority of the ~~outstanding shares~~capital stock of ~~Class B~~the Company entitled to vote and without a separate class vote of the common stock.

The holders of common stock ~~agree~~are entitled to ~~waive such adjustment~~receive dividends from time to time as may be declared by the Company’s board of directors. Through September 30, 2021, 0 dividends have been declared.

The holders of common stock are entitled to 1 vote for each share held with respect to ~~any such issuance or deemed issuance) so that~~all matters voted on by the common stockholders of the Company.

In the event of a reorganization of the Company, after payment to the preferred stockholders of their liquidation preferences, holders of common stock are entitled to share ratably in all remaining assets of the Company.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

As of September 30, 2021, the Company had reserved common stock for future issuances as follows:


		September 30,
		2021
Common stock reserved for Contingent Consideration Shares		15,000,000
Exercise of options under stock plans		6,399,888
Issuance of options under stock plans		7,730,503
Shares available for grant under ESPP		1,030,033
Warrants to purchase common stock		5,465,204
		35,625,628

On August 26, 2021, upon the Closing, all of the outstanding redeemable convertible preferred stock was converted to Common Stock pursuant to the conversion rate effective immediately prior to the Merger and the Exchange Ratio and the remaining amount was reclassified to additional paid-in capital.

Preferred Stock

The Company’s Second Amended and Restated Certificate of Incorporation provides the Company’s board of directors with the authority to issue $0.0001 par value preferred stock in one more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of ~~Class A~~designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were 20,000,000 shares designated as preferred stock and NaN were outstanding as of September 30, 2021.

Warrants

Activity of warrants for the nine months ended September 30, 2021 is set forth below:


	Legacy
	Humacyte
	Common Stock	Private Placement		Total Common
	Warrants	Warrants	Public Warrants	Stock Warrants

Outstanding as of December 31, 2020	32,961	—	—	32,961
Common Stock Warrants issued to SVB	287,704	—	—	287,704
Common Stock Warrants as Part of the Merger	—	177,500	5,000,000	5,177,500
Warrants Exercised	(32,961)	—	—	(32,961)
Oustanding as of September 30, 2021	287,704	177,500	5,000,000	5,465,204

In conjunction with a long-term debt agreement entered into on March 15, 2006 and paid in full during 2011, the Company issued a warrant that gave the holder the right to purchase 32,961 shares of the Company’s common stock ~~issuable upon conversion~~at an exercise price of ~~all shares~~$1.14 per share, which was outstanding as of ~~Class B common stock will equal,~~December 31, 2020. The warrant was fully exercised on March 4, 2021. There was no activity for the warrant during the year ended December 31, 2020.

See Note 7 – Debt for a discussion of warrants issued in conjunction with the ~~aggregate,~~Company’s Loan Agreement.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Private Placement Warrants

The Private Placement Warrants were initially recognized as a liability on ~~an as-converted basis, 20%~~the Closing Date, at a fair value of $0.6 million, and the ~~sum~~Private Placement Warrant liability was remeasured to fair value as of September 30, 2021, resulting in a loss of less than $0.1 million for the ~~total number of all shares~~three and nine months ended September 30, 2021, classified within change in fair value of common stock outstanding upon the completion of the IPO (excluding the placement units and underlying securities) plus all shares of Class A common stock and equity-linked securities issued or deemed issued in connection with the initial business combination (excluding any shares or equity-linked securities issued, or to be issued, to any sellerwarrant liabilities in the ~~initial business combination or any private placement-equivalent units~~condensed consolidated statements of operations and their underlying securities issued to our sponsor or its affiliates upon conversion of loans made to us). The term “equity-linked securities” refers to any debt or equity securities that are convertible, exercisable or exchangeable for shares of Class A common stock issued in a financing transaction in connection with our initial business combination, including but not limited to a private placement of equity or debt. Securities could be “deemed issued” for purposes of the conversion rate adjustment if such shares are issuable upon the conversion or exercise of convertible securities, warrants or similar securities.comprehensive loss.

The ~~holders of~~Private Placement Warrants were valued using the founder shares have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (A) one year after the completion of our initial business combination and (B) subsequent to our initial business combination, (x) if the reported last sale price of our Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after our initial business combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property (except as described hereinfollowing assumptions under the ~~section~~Monte Carlo simulation value model:


	September 30,			August 26,
	2021			2021
Market price of public stock	$	11.61		$	10.96
Exercise price	$	11.50		$	11.50
Expected term (years)		4.91			5.00
Expected share price volatility		28.5	%		32.5	%
Risk-free interest rate		0.96	%		0.68	%
Estimated dividend yield		0	%		0	%

Public Warrants

The Public Warrants may only be exercised for a whole number of this prospectus entitled “Principal Stockholders — Restrictions on Transfers of Founder Shares and Placement Units”). Any permitted transferees will be subject to the same restrictions and other agreements of our initial stockholders with respect to any founder shares.

~~Warrants~~ — Each whole warrant entitles the registered holder to purchase one share of Class A common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the later of 12 months from the closing of the IPO and 30 days after the completion of our initial business combination,shares and will expire five years after the completion of the ~~Company’s initial business combination, or earlier upon redemption or liquidation.~~

Merger. The Public Warrants became exercisable 30 days after the completion of the Merger.

The ~~Company~~Public Warrants were initially recognized as equity on the Closing Date at a fair value of $2.80 per share. There were 0 exercises of the Public Warrants during the three months ended September 30, 2021.

Contingent Earnout Liability

Following the Closing, former holders of Legacy Humacyte common and preferred shares may ~~redeem outstanding warrants (excluding~~receive up to 15,000,000 additional shares of the ~~warrants contained~~Company’s common stock in the ~~private units) at a price~~aggregate, in 2 equal tranches of ~~$0.01~~7,500,000 shares of common stock per ~~warrant i) at any time while the warrants~~tranche. The first and second tranches are ~~exercisable; ii) upon a minimum of 30 days prior written notice of redemption; iii) if, and only~~issuable if the ~~reported last sale~~closing volume weighted average price (“VWAP”) per share of ~~the~~ common stock ~~equals~~quoted on the Nasdaq (or the exchange on which the shares of common stock are then listed) is greater or ~~exceeds $18.00 per share, for~~equal to $15.00 and $20.00, respectively, over any 20 trading days within any thirty-day trading period.

Upon the Closing, the contingent obligation to issue Contingent Earnout Shares was accounted for as a ~~30 trading day period commencing once~~liability because the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders and iv) if, and only if, there is a current registration statement in effect with respect to the shares of Class A common stock underlying such warrants at the time of redemption and for the entire 30-day trading period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.

~~If the Company calls the warrants for redemption as described above, our management will have the option to require all holders~~triggering events that wish to exercise warrants to do so on a “cashless basis.” In determining whether to require all holders to exercise their warrants on a “cashless basis,” our management will consider, among other factors, our cash position,determine the number of ~~warrants~~Contingent Earnout Shares required to be issued include events that are ~~outstanding~~not solely indexed to the common stock of Humacyte. The estimated fair value of the total Contingent Earnout Shares at the Closing on August 26, 2021, was $159.4 million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over a ten-year period using the most reliable information available. The Contingent Earnout Liability was remeasured to fair value as of September 30, 2021, resulting in the recording of a non-cash loss of $9.8 million for the three and nine months ended September 30, 2021, classified within change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Assumptions used in the valuations are described below:


	September 30,			August 26,
	2021			2021
Current stock price	$	11.61		$	10.96
Expected share price volatility		78.9	%		79.6	%
Risk-free interest rate		1.55	%		1.34	%
Estimated dividend yield		0.0	%		0	%
Expected term (years)		10.00			10.00

9. Stock-based Compensation

At Closing, the 2021 Long-Term Incentive Plan, or the 2021 Plan, and the ~~dilutive effect on our stockholders~~2021 Employee Stock Purchase Plan, or the ESPP, became effective. As of ~~issuing the maximum number of~~September 30, 2021, 7,730,503 and 1,030,033 shares of ~~Class A~~ common stock ~~issuable upon~~were available under the ~~exercise~~2021 Plan and ESPP, respectively. On January 1 of ~~our warrants. In such event,~~ each ~~holder would pay~~year commencing January 1, 2022, the ~~exercise price by surrendering~~2021 Plan and the ~~warrants for that number of shares of Class A common stock~~ESPP reserve will automatically increase in an amount equal to the ~~quotient obtained by dividing (x) the product~~lesser of (a) 5% and 1%, respectively, of the number of shares of ~~Class A~~the Company’s common stock ~~underlying the warrants, multiplied by the difference between the exercise price~~outstanding on December 31 of the ~~warrants~~preceding year and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” for this purpose shall mean the average reported last sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

~~The exercise price and~~(b) a number of shares of common stock ~~issuable on exercise~~determined by the Company’s board of directors.

Under the 2021 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards. Under the ESPP, eligible employees are permitted to purchase shares of the ~~warrants~~Company's common stock at the lower of 85% of the closing trading price per share of the Company's common stock on the first day of the offering or 85% of the closing trading price per share on the exercise date, which will occur on the last day of each offering.

Prior to the Closing, Legacy Humacyte had 2 equity incentive plans, the 2015 Omnibus Incentive Plan, as amended, or the 2015 Plan, and the 2005 Stock Option Plan, or the 2005 Plan. As a result of the Merger, no further awards may be granted under either the 2015 plan or the 2005 Plan. All awards previously granted and outstanding as of the effective date of the Merger, which total 5,886,706 and 518,432 shares of common stock reserved for options issued under the 2015 Plan and 2005 Plan, respectively, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2015 Plan that are forfeited, cancelled or reacquired by the Company prior to vesting, that expire or that are paid out in cash rather than shares will become available for grant and issuance under the 2021 Plan.

The Company’s stock option plans allow for the grant of awards that the Company believes aid in aligning the interests of these persons with those of its stockholders. The Company’s board of directors determines the specific terms of equity incentive grants, including the exercise price per share and vesting period for option awards. Option awards are granted with an exercise price equal to the fair market value of the Company’s common stock at the date of grant.

The Company has granted options that include either a service-based or performance-based vesting conditions, or both, and a 10-year contractual term. The service-based vesting condition for the plans is generally satisfied over 36 to 48 months from the date of grant. The performance-based vesting conditions are satisfied upon the attainment of certain ~~circumstances~~product development milestones. The Company recognizes stock-based compensation expense based on the grant date fair value of the awards measured using the Black-Scholes option pricing model. Compensation expense related to awards with service-based vesting conditions is recognized on a straight-line basis over the requisite service period. Option valuation models, including the Black-Scholes option-pricing model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, the expected term of the award, and the fair value of the underlying common stock on the date of grant. Forfeitures are accounted for as they occur.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Compensation expense related to awards with performance-based vesting conditions is recognized over the requisite service period using the accelerated attribution method to the extent achievement of the performance-based condition is probable. The Company does not recognize compensation expense related to awards with performance-based vesting conditions until it is probable that the performance-based vesting condition will be achieved. Forfeitures are accounted for as they occur.

Option awards under the Company’s option plans generally provide for accelerated vesting of the unvested portions of any option award in the event of an involuntary termination, as such term is defined in the relevant stock option agreement, of a grantee’s employment during the period that commences 30days prior to the effective date of a corporate transaction and that ends 12 months following the effective date of such transaction. Additionally, the Company’s board of directors may, in its sole discretion, accelerate the vesting of any unvested stock options in the event of a ~~stock dividend, extraordinary dividend or~~corporate transaction.

Under the ~~Company’s recapitalization, reorganization, merger or consolidation. If~~terms of her employment agreement, the Company ~~(x) issues additional~~awarded the Company's President and Chief Executive Officer, Laura Niklason M.D., PhD., a stock option award in January 2021 entitling her to purchase 1,312,984 shares of ~~Class A~~the Company's common stock ~~or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination~~ at an ~~issue price or effective issue~~exercise price of ~~less than $9.20~~$10.28 per share, none of ~~Class A common~~which have vested as of September 30, 2021. This stock ~~(with such issue price or effective issue price~~option vests in equal annual installments on each of the first three anniversaries of November 9, 2020, subject to ~~be determined in good faith by our board of directors and,~~acceleration upon a corporate transaction (as defined in the ~~case~~2015 Plan). The vesting of any such issuance to our sponsor or its affiliates, without taking into account any founder shares held by our sponsor or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from such issuances represent more than 60%this award did not accelerate upon finalization of the ~~total equity proceeds, and interest thereon, available for~~Merger.

The Company estimated the ~~funding~~fair value of ~~our initial business combination~~the stock options on the date of grant using the ~~consummation~~following assumptions in the Black-Scholes option-pricing model:


	Three Months Ended September 30,			Nine Months Ended September 30,
	2021 (1)	2020		2021		2020

Estimated dividend yield	—	0	%	0	%	0	%
Expected share price volatility (weighted average and range, if applicable)	—	91.6	%	91.4% (91.0% to 92.1%)		91.4% (89.4% to 91.6%)
Risk-free interest rate (weighted average and range, if applicable)	—	0.34	%	0.68% (0.62% to 1.02%)		0.40% (0.34% to 0.75%)
Expected term of options (in years)	—	6.0		6.0		6.0

(1)	The Company did not grant any stock options during the three months ended September 30, 2021.

●

Fair Value of Common Stock.As the Company’s common stock was not publicly traded prior to the Merger, the fair value of the shares of its common stock underlying the options has historically been determined by the Company’s board of directors with input from management, after considering independent third-party valuation reports.

●

Expected Term.The expected term represents the period that stock options are expected to be outstanding. The Company calculated the expected term using the simplified method for options, which is available where there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

●

Expected Volatility.The expected volatility was based on the historical share volatility of several publicly traded peer companies over a period of time equal to the expected term of the options, as the Company does not have any trading history to use the volatility of its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

●

Risk-Free Interest Rate.The risk-free interest rate was based on the yields of U.S. Treasury zero-coupon securities with maturities similar in duration to the expected term of the options.

●

Expected Dividend Yield.The Company has not paid dividends on its common stock nor does it expect to pay dividends in the foreseeable future. Accordingly, the Company has estimated the dividend yield to be zero.

At September 30, 2021, there were 7,730,503 options remaining available for grant under the 2021 Plan. The Company has sufficient authorized and unissued shares to make all issuances currently available under the 2021 Plan.

The following tables show a summary of stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2021, and the three and nine months ended September 30, 2020, and remaining unrecognized cost as of September 30, 2021 and 2020:


	Three Months Ended September 30,				Nine Months Ended September 30,
($ in thousands)	2021		2020		2021		2020
Research and development	$	486	$	308	$	1,837	$	781
General and administrative		1,391		862		5,498		2,685
Total	$	1,877	$	1,170	$	7,335	$	3,466


	September 30,		December 31,
($ in thousands)	2021		2020

Unrecognized share-based compensation cost	$	12,480	$	5,789
Expected weighted average period compensation costs to be recognized (years)		2.1		1.7

A summary of option activity under the Company’s stock option plans during the nine months ended September 30, 2021 is presented below:


				Weighted
				Average
		Weighted		Remaining	Aggregate
		Average Exercise		Contractual Term	Intrinsic Value
	Number of Shares	Price Per Share		(years)	(in thousands)
Options outstanding at December 31, 2020	4,813,262	$	6.04	6.6	$	20,422
Granted	1,838,029	$	10.28
Exercised	(188,006)	$	2.97
Forfeited	(63,397)	$	7.87
Options outstanding at September 30, 2021	6,399,888	$	7.33	6.6	$	26,705
Vested and exercisable, September 30, 2021	4,092,342	$	5.74	5.1	$	23,345
Vested and expected to vest, September 30, 2021	6,399,888	$	7.33	6.6	$	26,705

The Company did not grant any stock options during the three months ended September 30, 2021.

10. Income Taxes

The Company’s tax provision for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate and, if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. No adjustment was made as of September 30, 2021. The Company’s effective federal tax rate for the three and nine months ended September 30, 2021 and 2020

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

was 0%, primarily as a result of estimated tax losses for the fiscal year to date offset by the increase in the valuation allowance in the net operating loss carryforwards.

The Company did not record any income tax expense or benefit during the three and nine months ended September 30, 2021 and 2020. The Company has a net operating loss and has provided a valuation allowance against net deferred tax assets due to uncertainties regarding the Company’s ability to realize these assets. All losses before income taxes arose in the United States.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was passed by the U.S. Congress and signed into United States law. The CARES Act, among other things, includes certain provisions for individuals and corporations; however, these benefits did not materially impact the Company’s income tax provision in the periods presented.

11. Commitments and Contingencies

Patent License Agreements

Duke University

In March2006, the Company entered into a license agreement with Duke University, or Duke, which was subsequently amended in 2011, 2014, 2015, 2018 and 2019. Under this license agreement, Duke granted the Company a worldwide, exclusive, sublicensable license to certain patents related to decellularized tissue engineering, referred to as the patent rights, as well as a non-exclusive license to use and practice certain know-how related to the patent rights. The relevant licensed patent on decellularization of tissue will expire in 2021. The Company has agreed to use commercially reasonable efforts to develop, register, market and sell products utilizing the patent rights, referred to as the licensed products. Any services provided to a third party utilizing licensed products are referred to as licensed services. The Company has also agreed to meet certain benchmarks in its development efforts, including as to development events, clinical trials, regulatory submissions and marketing approval, within specified timeframes. Under the license agreement, Duke retains the right to use the patent rights for its own educational and research purposes, and to provide the patent rights to other non-profit, governmental or higher-learning institutions for non-commercial purposes without paying royalties or other fees.

In connection with the Company’s entry into the license agreement, the Company granted equity consideration to Duke in the form of 52,693 shares of the Company’s common stock. Under the license agreement, the Company also agreed to pay Duke:

●

a low single-digit percentage royalty on eligible sales of licensed products and licensed services, plus a low double-digit percentage of any sublicensing revenue;

●

an annual minimum royalty beginning in 2012, which increases in the calendar year immediately following the first commercial sale of licensed products or licensed services (whichever occurs first); and

●

an additional amount in license fees, as certain milestones are met.

The license agreement remains effective until the last of the patent rights expires or four years after the Company’s first commercial sale, unless earlier terminated. Either party may terminate the agreement for fraud, willful misconduct or illegal conduct, or uncured material breach. Duke may terminate the agreement if the Company becomes insolvent. Duke may also terminate the license, convert the license into a non-exclusive license or seek assignment of any sublicense if the Company fails to reach diligence milestones within the applicable time period. If the Company abandons any claim, patent or patent application, its rights under the license with respect to such patent rights will be terminated in the territory in which the Company abandons such rights. The Company may terminate the license agreement unilaterally upon three months’ prior notice to Duke. The Company agrees to indemnify Duke against certain third-party claims. Payments to Duke under the license agreement were immaterial during the periods presented.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Yale University

In February2014, the Company entered into a license agreement with Yale University, or Yale, that granted the Company a worldwide license to the patents related to coatings for small-diameter vessels to inhibit clotting. The license granted under the agreement is exclusive in the field of engineered vascular tissues and tissues and extracellular matrix-based implants used for vascular repair, reconstruction and replacement (provided that all uses are vascular tissues within the range of 1-12mm in diameter), except that it is subject to Yale’s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.

In August2019, the Company entered into a license agreement with Yale, that granted the Company a worldwide license to the patents related to Bioartificial Vascular Pancreas (BVP). The license granted under the agreement is exclusive in the field of engineered vascular tissues that deliver pancreatic islet cells to patients, except that it is subject to Yale’s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.

In August2019, the Company entered into a license agreement with Yale that granted the Company a worldwide license to the patents related to tubular prostheses. The license granted under the agreement is exclusive in the field of engineered urinary conduits, engineered tracheas/airways, and engineered esophagi, except that it is subject to Yale’s non-exclusive right, on behalf of itself and all other non-profit academic institutions, to use the licensed products for research, teaching, and other non-commercial purposes. The Company has agreed to pay to Yale an annual maintenance fee, increasing between the first and fourth anniversaries of the agreement up to a maximum of less than $0.1 million per year for this license.

The Company has agreed to use reasonable commercial efforts to develop and commercialize the licensed patents and any licensed products and methods, and to use reasonable efforts to make the licensed products available to patients in low and low-middle income countries. The Company is also obligated to provide Yale periodically an updated and revised copy of its plan for each license, which must indicate progress of its development and commercialization. The Company may also sublicense the Company’s rights without Yale’s prior written consent, but such sublicense is subject to certain conditions.

In connection with its entry into the license agreement, the Company paid Yale upfront cash fees. The Company has also agreed to pay Yale:

●

annual maintenance fees, increasing between the first anniversary of the agreement until the fifth anniversary for the coating and BVP licenses and until the fourth anniversary for the tubular prostheses license up to a maximum of less than $0.1 million per year;

●

milestone payments upon achievement of certain regulatory and commercial milestones of $0.2 million and $0.6 million;

●

a low single-digit percentage royalty on worldwide net sales, subject to reductions for third-party license fees; and

●

a low double-digit percentage of sublicensing income.

If the Company or any of its future sublicensees bring a patent challenge against Yale or assists another party in bringing a patent challenge against Yale, the license fees described above will be subject to certain increases and penalties.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

The agreements expire on a country-by-country basis on the date on which the last of the patents in such country expires, lapses or is declared invalid. Yale may terminate the agreements if the Company fails to (i)provide written diligence reports, (ii)provide commercially reasonable diligence plans, (iii)implement the plans in accordance with the obligations under the agreements, or (iv)reach certain research and development milestones within the scheduled timeframe set forth in the agreements; however, any such termination right would be limited in scope to the country to which such failure relates. Yale may also terminate for the Company’s non-payment, uncured material breach, failure to obtain adequate insurance, bringing or assisting in bringing of a patent challenge against Yale, abandonment of the research and development of the Company’s products or insolvency. The Company may terminate the license agreements (i)on 90days’ prior written notice to Yale, provided the Company is not in breach of the license agreements and has made all required payments to Yale thereunder and (ii)on written notice to Yale following an uncured material breach. With respect to the license agreements related to small-diameter vessels and BVP, the Company’s rights under the license agreements will also terminate automatically with respect to a patent application or patent within the licensed patents in a specified country if, upon receipt of written notice from Yale, the Company does not agree to pay the patent filing, prosecution and maintenance fees incurred by Yale for such patent applications or patents in the specified country. Under certain circumstances, Yale may, at its option, convert the exclusive licenses to non-exclusive licenses if the Company declines to initiate certain infringement or interference proceedings with respect to the licensed patents. The Company has agreed to indemnify Yale against certain third-party claims. Payments to Yale under the license agreement were immaterial during the periods presented.

Legal Matters

The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company’s business, financial condition, results of operations, or cash flows.

Indemnification

To the extent permitted under Delaware law, the Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification arrangements is not specified in such arrangements; however, the Company has director and officer insurance coverage that is intended to reduce its exposure and enable the Company to recover a portion of any potential future amounts the Company could be required to make. To date, the Company has not incurred any costs as a result of such obligations and has not accrued any liabilities related to such obligations in the condensed consolidated financial statements.

12. Related Party Transactions

Fresenius Medical Care investments and distribution agreement

In June 2018, the Company completed a $150 million financing transaction pursuant to which Fresenius Medical Care purchased shares of series D redeemable convertible preferred stock that at the Closing of the Merger converted into 15,812,735 shares of the Company’s common stock. In August 2021, Fresenius Medical Care invested $25 million as part of the PIPE Financing and received 2.5 million shares of the Company’s common stock.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

In addition, the Company entered into a distribution agreement with Fresenius Medical Care in June 2018 which, as amended as of February 16, 2021, granted Fresenius Medical Care and its affiliates exclusive rights to develop outside the United States and EU and commercialize outside of the United States the Company’s 6 millimeter x 42cm HAV and all improvements thereto, and modifications and derivatives thereof (including any changes to the length, diameter or configuration of the foregoing), for use in vascular creation, repair, replacement or construction, including renal replacement therapy for dialysis access, the treatment of peripheral arterial disease, and the treatment of vascular trauma, but excluding coronary artery bypass graft, pediatric heart surgery, or adhering pancreatic islet cells onto the outer surface of the distribution product for use in diabetic patients. Within the United States, Fresenius Medical Care will collaborate with the Company in its commercialization of the product in the field, including adoption of the distribution product as a standard of care in patients for which such use is supported by clinical results and health economic analyses.

The Company is responsible for developing and seeking regulatory approval for the distribution product in the field in the United States. For countries outside the United States, the parties agreed to use commercially reasonable efforts to satisfy certain agreed minimum market entry criteria for the distribution product in the field in such country. For the EU, once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory approval for the distribution product in the field in the applicable country, the Company agreed to use commercially reasonable efforts to obtain such regulatory approval (other than pricing approval), and Fresenius Medical Care agreed to use commercially reasonable efforts to obtain the corresponding pricing approval. For the rest of the world (i.e., outside the United States and the EU), once such criteria have been satisfied for the applicable country, or if the parties otherwise mutually agree to obtain regulatory and pricing approval for the distribution product in the field in the applicable country, Fresenius Medical Care agreed to use commercially reasonable efforts to obtain such approvals, and the Company agreed to use commercially reasonable efforts to support Fresenius Medical Care in its efforts.

Under the distribution agreement, the Company grants an exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to commercialize the distribution product in the field outside the United States, subject to the Company’s retained rights to carry out its obligations under the distribution agreement. The Company also grants a non-exclusive, sublicensable license to Fresenius Medical Care under the patents, know-how and regulatory materials controlled by the Company during the term to develop the distribution product in accordance with the terms of the distribution agreement. In addition, the Company grants to Fresenius Medical Care, among other things, a perpetual, irrevocable, non-exclusive sublicensable license under the patents and know-how that primarily relate to the distribution product or its manufacture and that were created, conceived or developed solely or jointly by or on behalf of Fresenius Medical Care in the performance of its activities under the distribution agreement.

The distribution agreement provides that the Company will own all know-how and patents that primarily relate to the distribution product or its manufacture that are created, conceived or developed by or on behalf of either party in the performance of activities under the distribution agreement. Ownership of all other know-how, patents, materials and other intellectual property created, conceived or developed during the performance of activities under the distribution agreement will be determined in accordance with U.S. patent laws for determining inventorship.

The Company is obligated to make payments to Fresenius Medical Care based on a share of aggregate net sales by or on behalf of the Company of the distribution product in the United States in the field. Such revenue-share payments will be a percentage of net sales in the low double digits, without regard to the calendar year in which such net sales are attributable, until such time that the Company has paid to Fresenius Medical Care a certain total amount, at which time the revenue-share will decrease to a percentage of net sales in the mid-single digits. The amounts that Fresenius Medical Care will be obligated to pay the Company under the distribution agreement for sales of the distribution product in the field outside of the United States will vary. Fresenius Medical Care agreed to pay the Company initially, on a country-by-country basis for sales outside of the United States, the amount equal to the average cost of manufacturing the Company’s distribution product plus a fixed dollar amount per unit. Following a specified period, on a country-by-country basis outside of the United States, Fresenius Medical Care will pay the Company a fixed percentage of net sales for each unit sold in such country, such that the Company will receive more than half of such net sales.

Table of Contents

Humacyte,Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

The distribution agreement will generally continue on a country-by-country basis until the later of (a) the tenth anniversary of the launch date of the distribution product in the relevant country or (b) the expiration of the last-to-expire valid claim of specified patents in such country. Each party is permitted to terminate the distribution agreement for insolvency of, or, under certain circumstances, including various cure periods, material breach by the other party. Subject to a cure period, Fresenius Medical Care may also terminate the distribution agreement in its entirety or on a country-by-country basis (i) for certain withdrawals of regulatory approval or (ii) for termination or expiration of any of our ~~initial business combination (net~~in-licenses that is necessary for the exercise of ~~redemptions), and (z)~~Fresenius Medical Care’s rights, or the ~~volume weighted average trading price~~satisfaction of ~~our Class A common stock during~~its obligations, under the ~~20 trading day period starting~~distribution agreement. In addition, Fresenius Medical Care may terminate the distribution agreement for convenience on a country-by-country basis upon not less than 12 months’ written notice to the ~~trading day~~Company, although Fresenius Medical Care is not permitted to give such notice prior to the ~~day on which we consummate our initial business combination (such price, the “Market Value”) is below $9.20 per share, then the exercise price~~end of the ~~warrants will be adjusted (to the nearest cent) to be equal to 115%~~second year following launch of the ~~greater~~distribution product in such country. Each party is required to indemnify one another for certain third-party claims.

Arrangements with Dr.Niklason and Yale University

In September2016, the Company entered into a Memorandum of Understanding Regarding Scientific and Operational Leadership, or MOU, with Dr.Niklason in connection with her performance of various consulting activities for the Company.

The MOU provided for the Company to make a payment each year through 2023 to the academic institution with which Dr.Niklason was then affiliated, up to an aggregate amount of $2.5 million for 2018 through 2023, and to pay Dr.Niklason reasonable consulting fees in consideration of the ~~Market Value~~services she performed for the Company. For the three and nine months ended September 30, 2020, the ~~Newly Issued Price,~~company made payments under the MOU of $0.1 million and $0.4 million, respectively, to, or on behalf of, Yale University, where Dr. Niklason, currently the ~~$18.00 per share redemption trigger price described below under “Redemption of warrants” will be adjusted (to the nearest cent) to be equal to 180%~~Company’s President, CEO and a member of the ~~greater~~Company’s board of ~~the Market Value~~directors, serves as a Professor Adjunct, Division Chief and ~~the Newly Issued Price.~~

~~Note 8 — Subsequent Events~~

Vice Chair, Research in Anesthesia. The MOU was terminated effective November 9, 2020.

The following table shows a summary of related party expenses included in the statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020:


	Three Months Ended September 30,		Nine Months Ended September 30,
($ in thousands)	2021	2020	2021	2020
Expenses under MOU	—	125	—	375
License expenses	—	20	85	70
Other	2	4	83	17
Total	2	149	168	462

As of September 30, 2021 and December 31, 2020, the Company was a party to license agreements with Yale University, as described in Note 11 — Commitments and Contingencies, above.

13. Subsequent Events

In preparing the condensed consolidated financial statements as of September 30, 2021 and for the three and nine months ended September 30, 2021, the Company evaluated the effect subsequent events ~~and transactions that occurred after~~would have on the ~~balance sheet date~~financial statements through the date ~~that~~ the financial statements were issued. ~~Based upon this review, other than as described above,~~

On October 13, 2021, the Company ~~did not identify any subsequent events that would have required adjustment or disclosure in~~borrowed an additional $10.0 million under the ~~financial statements.~~Loan Agreement, and the warrants to purchase an additional 123,302 shares of the Company’s common stock at an exercise price of $10.28 per share became exercisable. See Note 7 – Debt and Note 8 – Stockholders’ Equity (Deficit) for additional information.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included under Part I, Item 1 of this Quarterly Report on Form 10-Q (this “Quarterly Report”). In addition, you should refer to our audited consolidated financial statements and the related notes for the year ended December 31, 2020 and the section entitled “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” included in the Company’s Registration Statement on Form S-1, filed with the SEC on September 17, 2021 and amended on October 22, 2021.

~~References~~Unless the context indicates otherwise, references in this Quarterly Report to the “Company,” ~~“our,~~“Humacyte,” ~~“us” or “we”~~“we,” “us,” “our” and similar terms refer to Humacyte, Inc. (formerly known as Alpha Healthcare Acquisition Corp.) and its consolidated subsidiaries (including Humacyte Global, Inc.) following the Company’s business combination with Alpha Healthcare Acquisition Corp (the “Business Combination”); references to “Legacy Humacyte” refer to Humacyte, Inc. prior to the Business Combination; and references to “AHAC” refer to Alpha Healthcare Acquisition Corp. ~~The following~~prior to the Business Combination.

Cautionary Statement Regarding Forward-Looking Statements

In addition to historical information, some of the information contained in this discussion and analysis ~~of the Company’s financial condition and results of operations should be read in conjunction with the unaudited financial statements and the notes thereto contained~~or set forth elsewhere in this ~~report. Certain~~Quarterly Report, including information ~~contained in the discussion~~with respect to our plans and ~~analysis set forth below~~strategy for our business, future financial performance, expense levels and liquidity sources, includes forward-looking statements that involve risks and uncertainties.

~~Cautionary Note Regarding Forward-Looking Statements~~

~~This~~ You should read the sections of this Quarterly Report ~~on Form 10-Q includes~~entitled “Forward-Looking Statements” and “Risk Factors” for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements ~~within~~contained in the ~~meaning~~following discussion and analysis.

Overview

We are pioneering the development and manufacture of ~~Section 27A~~off-the-shelf, universally implantable, bioengineered human tissues designed to improve the lives of patients and transform the practice of medicine. We believe our technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement. We are leveraging our novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues. Our goal is to develop and manufacture these tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

We are initially using our proprietary scientific technology platform to engineer and manufacture our bioengineered human, acellular tissue-based vessels (“HAVs”). Our HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. We are developing our “cabinet” of HAVs of varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including use in AVs access for hemodialysis, trauma, peripheral arterial disease and coronary artery bypass graft. In addition, we are developing our HAVs as conduits for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation for the treatment of Type 1 diabetes (our biovascular pancreas). We intend to continue to explore the application of our technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus and other novel cell delivery systems.

We believe there is substantial clinical demand for safe and effective vascular conduits to replace and repair blood vessels throughout the body. Vascular injuries resulting from trauma are common in civilian and military populations, frequently resulting in the loss of either life or limb. Existing treatment options in the vascular repair, reconstruction and replacement market use autologous vessels and synthetic grafts and suffer from significant limitations. For example, the use of autologous veins to repair traumatic vascular injuries can lead to significant morbidity associated with the surgical wounds created for vein harvest and prolonged times to restore blood flow to injured limbs leading to an increased risk of amputation and infection. Synthetic grafts are often contraindicated in the setting of vascular trauma due to higher infection risk that can lead to prolonged hospitalization and limb loss. Given the competitive advantages HAVs may have over existing vascular substitutes, we believe that HAVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs.

Table of Contents

We have generated no product revenue and incurred losses and negative cash flows from operations in each year since our inception in 2004. As of September 30, 2021 and December 31, 2020, we had an accumulated deficit of $457.2 and $388.1 million, respectively, and working capital of $222.9 million and $30.2 million, respectively. Our net losses were approximately $31.6 million and $69.1 million for the three and nine months ended September 30, 2021, respectively, and $17.8 million and $50.3 million for the three and nine months ended September 30, 2020, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its product candidates.

As of September 30, 2021 and December 31, 2020, we had cash and cash equivalents of $240.4 million and $39.9 million, respectively. We believe our cash and cash equivalents will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, for at least 12 months from the date of this Quarterly Report. See Note 1, “Organization and Description of Business,” in the notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report for additional information regarding this assessment.

Recent Developments

Closing of Merger

On August 26, 2021 (the “Closing Date”), Legacy Humacyte and AHAC consummated the Business Combination pursuant to the Business Combination Agreement (the “Merger Agreement”), by and among Legacy Humacyte, AHAC and Hunter Merger Sub, Inc. (“Merger Sub”). As contemplated by the Business Combination Agreement, Merger Sub merged with and into Legacy Humacyte, with Legacy Humacyte surviving the Merger as a wholly owned subsidiary of AHAC (such transactions, the “Merger”). As a result of the ~~Securities Act~~Merger, AHAC was renamed Humacyte, Inc. and Legacy Humacyte was renamed Humacyte Global, Inc.

Pursuant to the terms of ~~1933, as amended~~the Merger Agreement, at the effective time of the Merger (the ~~“Securities Act”~~“Effective Time”), (1) each outstanding share of common stock of Legacy Humacyte (“Legacy Humacyte common stock”) was cancelled and converted into the right to receive approximately 0.26260 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), and ~~Section 21E~~(2) each outstanding share of preferred stock of Legacy Humacyte (“Legacy Humacyte preferred stock”) was cancelled and converted into the aggregate number of shares of Common Stock that would be issued upon conversion of the shares of Legacy Humacyte preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by approximately 0.26260, resulting in the issuance of a total of 75,656,935 shares of Common Stock. Prior holders of shares of Legacy Humacyte common stock and Legacy Humacyte preferred stock also received the contingent right to receive certain Earnout Shares (as defined below), for each share owned by each such Legacy Humacyte stockholder that was outstanding immediately prior to the closing of the Merger (the “Closing”). In addition, certain investors purchased an aggregate of 17,500,000 shares of Common Stock (such investors, the “PIPE Investors”) in a private placement that closed concurrently with the Closing for an aggregate purchase price of $175 million (the “PIPE Financing”). Additionally, at the Closing, 2,500,000 shares of AHAC’s Class B common stock (“Founder Shares”) automatically converted into shares of Common Stock on a one-for-one basis.

Pursuant to the terms of the Merger Agreement, at the Effective Time of the Merger, (1) warrants to purchase shares of Legacy Humacyte common stock were converted into warrants to purchase an aggregate of 287,704 shares of Common Stock, and (2) options to purchase shares of Legacy Humacyte common stock were converted into options to purchase an aggregate of 6,405,138 shares of Common Stock.

Following the Closing Date, former holders of Legacy Humacyte common stock and Legacy Humacyte preferred stock may receive up to 15,000,000 additional shares of Common Stock (“Earnout Shares”) in the aggregate in two equal tranches if the volume-weighted average closing sale price of our Common Stock is greater than or equal to $15.00 and $20.00, respectively, for any 20 trading days within any 30 consecutive trading day period.

Table of Contents

Impact of COVID-19

The COVID-19 pandemic, which began in December 2019 and has spread worldwide, has caused many governments to implement measures to slow the spread of the outbreak, including shelter-in-place orders and the mandatory shutdown of certain businesses. The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on our business, as supply chains have been disrupted, and facilities and production have been suspended. The future progression of the pandemic and its effects on our business and operations are uncertain. The COVID-19 pandemic may affect our ability to initiate and complete preclinical studies, delay our clinical trials or future clinical trials, disrupt regulatory activities, or have other adverse effects on our business and operations. The pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds to support our operations. Moreover, the pandemic has significantly impacted economies worldwide and could result in adverse effects on our business and operations.

To date, the COVID-19 pandemic has not resulted in material financial impacts or impairment losses in the carrying values of our assets as a result of the pandemic and we are not aware of any specific related event or circumstance that would require us to revise the estimates reflected in our financial statements. The extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including current and future clinical trials and research and development costs, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related economic impact of the pandemic.

Components of Results of Operations

Revenue

To date, we have not generated revenue from the sale of any products. All of our revenue has been derived from government and other grants. Since inception we have been awarded grants from the California Institute of Regenerative Medicine (“CIRM”), the National Institutes of Health (“NIH”), and the Department of Defense (“DoD”), to support our development, production scaling and clinical trials of our product candidates. We recognized $30.8 million in revenue from inception to September 30, 2021 from these sources, including $11.2 million from CIRM under a program that ended in 2020. We may generate revenue in the future from government and other grants, payments from future license or collaboration agreements and, if any of our product candidates receive marketing approval, from product sales. We expect that any revenue we generate will fluctuate from quarter to quarter. If we fail to complete the development of, or obtain marketing approval for, our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.

Research and Development Expenses

Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, developing our manufacturing process and activities related to regulatory filings for our product candidates. We recognize research and development expenses as they are incurred. Our research and development expenses consist primarily of:

●

salaries and related overhead expenses for personnel in research and development functions, including stock-based compensation and benefits;

●

fees paid to consultants and clinical research organizations (“CROs”), including in connection with our clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work and statistical compilation and analysis;

●

allocation of facility lease and maintenance costs;

●

depreciation of leasehold improvements, laboratory equipment and computers;

●

costs related to purchasing raw materials for and producing our product candidates for clinical trials;

●

costs related to compliance with regulatory requirements;

Table of Contents

●

costs related to our manufacturing development and expanded-capabilities initiatives; and

●

license fees related to in-licensed technologies.

The majority of our research and development resources are currently focused on our Phase III clinical trials for our 6 millimeter HAV and other work needed to obtain marketing approval for our 6 millimeter HAV for use for vascular repair, reconstruction and replacement, including trauma and arteriovenous (“AV”) access in hemodialysis in the United States and Europe. We have incurred and expect to continue to incur significant expenses in connection with these and our other clinical development efforts, including expenses related to regulatory filings, trial enrollment and conduct, data analysis, patient follow up and study report generation for our Phase II and Phase III clinical trials. We do not allocate our costs by each research and development program for which we are developing our cabinet of HAVs, as a significant amount of our development activities broadly support multiple programs that use our technology platform. We plan to further increase our research and development expenses for the foreseeable future as we continue the development of our proprietary scientific technology platform and our novel manufacturing paradigm.

The successful development of our preclinical and clinical product candidates is highly uncertain. At this time, we cannot estimate with any reasonable certainty the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our preclinical or clinical product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our product candidates, including:

●

the scope, rate of progress, expense and results of our preclinical development activities, our ongoing clinical trials and any additional clinical trials that we may conduct, and other research and development activities;

●

successful patient enrollment in and the initiation and completion of clinical trials;

●

the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration (“FDA”) and non-U.S. regulators;

●

the extent of any required post-marketing approval commitments to applicable regulatory authorities;

●

development of clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that it or its third-party manufacturers are able to successfully manufacture our product;

●

obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;

●

significant and changing government regulations;

●

launching commercial sales of our product candidates, if approved, whether alone or in collaboration with others;

●

the degree of market acceptance of any product candidates that obtain marketing approval; and

●

maintaining a continued acceptable safety profile following approval, if any, of our product candidates.

A change in the outcome of any of these variables could lead to significant changes in the costs and timing associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate being required to conduct in order to complete the clinical development of any of our product candidates, or if we experience significant delays in the enrollment or the conduct of any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development.

Table of Contents

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs for employees in executive, finance, human resources, commercialization, and administrative support functions, which also include stock-based compensation expenses and benefits for such employees. Other significant general and administrative expenses include facilities costs, professional fees for accounting and legal services and expenses associated with obtaining and maintaining patents.

We expect our general and administrative expenses will increase for the foreseeable future to support our expanded infrastructure and increased costs of operating as a public company. These increases are expected to include increased employee-related expenses and increased director and officer insurance premiums, audit and legal fees, investor relations fees and expenses for compliance with public company reporting requirements under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)~~. We have based these forward-looking statements on our current expectations~~ and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or impliedrules implemented by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Such statements include, but are not limited to, possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this Form 10-Q. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other Securities and Exchange Commission ~~(“SEC”~~(the “SEC”) ~~filings.~~, as well as the rules of the Nasdaq Global Select Market.

Total Other Expenses, Net

~~Overview~~

~~We are a blank check company incorporated~~Total other expenses, net consists of (i) the change in fair value of the contingent earnout liability that was accounted for as a ~~Delaware corporation~~liability as of the date of the Merger, and ~~formed for the purpose of effecting~~is remeasured to fair value at each reporting period, resulting in a ~~merger, capital stock exchange, asset acquisition, stock purchase, reorganization~~non-cash gain or ~~similar business combination with one or more businesses. While our efforts to identify~~loss, (ii) a target business may span many industries and regions worldwide, we intend to focus our search for prospects within the healthcare industry in the United States. We have not selected any specific business combination target and we have not, nor has anyonegain on Paycheck Protection Program (“PPP”) loan forgiveness, (iii) interest income earned on our ~~behalf, initiated any substantive discussions, directly or indirectly,~~cash and cash equivalents, (iv) interest expense incurred on our term loan agreement with ~~any business combination target. We intend to effectuate~~Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. (the “Loan Agreement”), finance leases, and our ~~initial business combination using cash from~~PPP loan during the ~~proceeds~~periods each were outstanding, (v) a change in fair value of ~~our IPO and the sale of the~~ private placement ~~units, the proceeds of the sale of our shares~~common stock warrant liabilities related to private placement warrants originally issued in a private placement to AHAC Sponsor LLC (“Private Placement Warrants”), which we assumed in connection with ~~our initial business combination (including pursuant~~the Merger, and which are subject to ~~backstop agreements we may enter into), shares issued~~remeasurement to ~~the owners of the target, debt issued~~fair value at each balance sheet date resulting in a non-cash gain or loss, and (vi) legal, accounting, and underwriting fees and other costs directly related to ~~bank or other lenders or the owners of the target, or a combination of the foregoing.~~

On September 22, 2020, we consummated our initial public offering (the “IPO”) of 10,000,000 units (the “Units”). Each Unit consists of one share of Class A common stock, par value $0.0001 per share (“Class A Common Stock”) and one-half of one redeemable warrant (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one share of Class A Common Stock for $11.50 per share. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to us of $100,000,000. We granted the underwriters in the IPO, a 45-day option to purchase up to 1,500,000 additional Units solely to cover over-allotments, if any. Oppenheimer & Co. Inc. acted as the sole book running manager and Northland Securities, Inc. acted as the co-manager of the IPO. The securities sold in the IPO were registered under the Securities Act on registration statements on Form S-1 No. 333-240374. The SEC declared the registration statement effective on September 17, 2020.

~~On September 22, 2020, simultaneously with~~ the consummation of the ~~IPO, we completed~~Merger that were associated with the ~~private sale (the “Private Placement”)~~aforementioned warrant liabilities.

Results of an aggregate of 355,000 Units (the “Private Placement Units”) to AHAC Sponsor LLC (our “Sponsor”), Oppenheimer & Co. Inc. and Northland Securities, Inc., generating gross proceeds to us of $3,550,000. Such securities were issued pursuant to the exemption from registration contained in Section 4(a)(2)Operations

Comparison of the ~~Securities Act.~~

A total of $100,000,000, comprised of $98,000,000 of the proceeds from the IPO and $2,000,000 of the proceeds of the sale of the Private Placement Units, was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee.

~~The issuance of additional shares in connection with an initial business combination to the owners of the target or other investors:~~

●

may significantly dilute the equity interest of investors, which dilution would increase if the anti-dilution provisions in the Class B common stock resulted in the issuance of Class A shares on a greater than one-to-one basis upon conversion of the Class B common stock;

●

~~may subordinate the rights of holders of our common stock if preferred stock is issued with rights senior to those afforded our common stock;~~

●

could cause a change in control if a substantial number of shares of our common stock is issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if any, and could result in the resignation or removal of our present officers and directors;

●

~~may have the effect of delaying or preventing a change of control of us by diluting the stock ownership or voting rights of a person seeking to obtain control of us; and~~

●

~~may adversely affect prevailing market prices for our Class A common stock and/or warrants.~~

~~Similarly, if we issue debt securities or otherwise incur significant debt to bank or other lenders or the owners of a target, it could result in:~~

●

~~default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations;~~

●

acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial ratios or reserves without a waiver or renegotiation of that covenant;

●

~~our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand;~~

●

~~our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding;~~

●

~~our inability to pay dividends on our common stock;~~

●

using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our common stock if declared, our ability to pay expenses, make capital expenditures and acquisitions, and fund other general corporate purposes;

●

~~limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate;~~

●

~~increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation;~~

●

~~limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, and execution of our strategy; and~~

●

~~other purposes and other disadvantages compared to our competitors who have less debt.~~

~~As indicated in the accompanying financial statements, as of~~Three Months Ended September 30, 2021 and 2020 we had $1,316,314 in cash. Further, we expect to incur significant costs in the pursuit of our initial Business Combination. We cannot assure you that our plans to raise capital or to complete our initial Business Combination will be successful.



	Three Months Ended September 30,				Change
($in thousands)	2021		2020			$	%
Revenue	$	241	$	914		(673)	(74)	%

Operating expenses:
Research and development		15,386		14,692		694	5	%
General and administrative		5,398		3,435		1,963	57	%
Total operating expenses		20,784		18,127		2,657	15	%
Loss from operations		(20,543)		(17,213)		(3,330)	(19)	%
Other expenses, net
Change in fair value of contingent earnout liability		(9,768)		—		(9,768)	100	%
Interest expense		(1,204)		(549)		(655)	(119)	%
Other (expenses) income, net		(48)		2		(50)	—
Total other expense, net		(11,020)		(547)		(10,473)	—	%
Net loss	$	(31,563)	$	(17,760)	$	(13,803)	(78)	%

~~Results of Operations and Known Trends or Future Events~~

We have neither engaged in any operations nor generated any revenues to date. Our only activities since inception have been organizational activities, those necessary to prepare for our Initial Public Offering and identifying a target company for our initial Business Combination. We do not expect to generate any operating revenues until after completion of our initial Business Combination. We generate non-operating income in the form of interest income on cash and cash equivalents held in the Trust Account. We incur expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well as expenses as we conduct due diligence on prospective Business Combination candidates.

Grant Revenue

For the three months ended September 30, 2021 and 2020, ~~we had~~revenue totaled $0.2 million and $0.9 million, respectively, a decrease of $0.7 million, or 74%. The decrease relates to $0.3 million of revenue recognized during the three months ended September 30, 2020 related to our grant from NIH before the program ended in 2020, and $0.4 million related to the timing of reimbursement of certain allowable costs related to our grant from DoD in the third quarter of 2020 as compared to the current year period.

Table of Contents

Research and Development Expenses

The following table discloses the breakdown of research and development expenses for the periods indicated:


	Three Months Ended September 30,				Change
($in thousands)	2021		2020		$		%
External services	$	3,801	$	3,696	$	105	3	%
Lab supplies		2,947		3,273		(326)	(10)	%
Payroll and personnel expenses		5,775		4,774		1,001	21	%
Other research and development expenses		2,863		2,949		(86)	(3)	%
	$	15,386	$	14,692		694	5	%

Research and development expenses increased from $14.7 million for the three months ended September 30, 2020 to $15.4 million for the three months ended September 30, 2021. The increase of $0.7 million, or 5%, was primarily driven by an increase in payroll and personnel expenses to support our research and development initiatives, including a $0.8 million increase in salaries and benefits and a $0.2 million increase in non-cash stock compensation expense, partially offset by a $0.3 million decrease in the purchase of lab supplies.

General and Administrative Expenses

General and administrative expenses were $5.4 million and $3.4 million for the three months ended September 30, 2021 and 2020, respectively. The increase in general and administrative expenses of $2.0 million, or 57%, was primarily driven by increases in professional fees of $0.6 million, including those related to preparations for commercial launch, non-cash stock compensation expense of $0.5 million, $0.3 million in insurance costs and $0.2 million in salaries and benefits.

Total Other Expenses, Net

Total other expense, net ~~loss~~was $11.0 million and $0.5 million for the three months ended September 30, 2021 and 2020, respectively. The increase of ~~$40,952,~~$10.5 million resulted from a $9.8 million non-cash expense related to the remeasurement of the contingent earnout liability as of September 30, 2021 and a $0.7 million increase in interest expense related to our loan facility with Silicon Valley Bank, which ~~consists~~commenced in March 2021.

Comparison of ~~formation~~the Nine Months Ended September 30, 2021 and ~~operating costs~~2020


	Nine Months Ended September 30,				Change
($ in thousands)	2021		2020		$		%
Revenue	$	1,086	$	1,367		(281)	(21)	%

Operating expenses:
Research and development		45,091		40,879		4,212	10	%
General and administrative		15,576		9,416		6,160	65	%
Total operating expenses		60,667		50,295		10,372	21	%
Loss from operations		(59,581)		(48,928)		(10,653)	(22)	%
Other expenses, net:
Gain on PPP loan forgiveness		3,284		—		3,284	0	%
Change in fair value of contingent earnout liability		(9,768)		—		(9,768)	100	%
Interest expense		(2,952)		(1,661)		(1,291)	(78)	%
Other (expenses) income, net		(45)		277		(322)	116	%
Total other expense, net		(9,481)		(1,384)		(8,097)	—
Net loss	$	(69,062)	$	(50,312)	$	(18,750)	(37)	%

Table of ~~$18,775~~Contents

Grant Revenue

For the nine months ended September 30, 2021 and 2020, revenue totaled $1.1 million and $1.4 million, respectively, a decrease of $0.3 million, or 21%. The decrease relates to $0.3 million of revenue recognized during the nine months ended September 30, 2020 related to our grant from NIH before the program ended in 2020.

Research and Development Expenses

The following table discloses the breakdown of research and development expenses for the periods indicated:


	Nine Months Ended September 30,				Change
($in thousands)	2021		2020		$		%
External services	$	11,534	$	10,748	$	786	7	%
Lab supplies		8,141		6,815		1,326	19	%
Payroll and personnel expenses		17,003		14,497		2,506	17	%
Other research and development expenses		8,413		8,819		(406)	(5)	%
	$	45,091	$	40,879	$	4,212	10	%

Research and development expenses increased from $40.9 million for the nine months ended September 30, 2020 to $45.1 million for the nine months ended September 30, 2021. The increase of $4.2 million, or 10%, was primarily driven by an ~~unrealized loss~~increase in payroll and personnel expenses, including a $1.4 million increase in salaries and benefits and a $1.1 million increase in non-cash stock compensation expense, and the purchase of lab supplies used to in the development of our commercial manufacturing process and in our research and development initiatives, including the preparation of clinical studies.

General and Administrative Expenses

General and administrative expenses were $15.6 million and $9.4 million for the nine months ended September 30, 2021 and 2020, respectively. The increase in general and administrative expenses of $6.2 million, or 65%, was driven by increases in non-cash stock compensation expense of $2.8 million, external services and professional fees of $1.7 million, including those related to preparations for commercial launch and corporate initiatives, $0.6 million in salaries and benefits, and $0.4 million in insurance costs.

Total Other Expenses, net

Total other expense, net was $9.5 million and $1.4 million for the nine months ended September 30, 2021 and 2020, respectively. The increase of $8.1 million resulted from a $9.8 million non-cash expense related to the remeasurement of the contingent earnout liability as of September 30, 2021, a $1.3 million increase in interest expense related to our loan facility with Silicon Valley Bank, which commenced in March 2021, and a $0.3 million decrease in interest income earned on ~~marketable securities held in Trust Account of $22,177.~~our cash equivalents due to lower interest rates and lower average cash balances during the year, partially offset by a $3.3 million gain on PPP loan forgiveness.

Liquidity and Capital Resources

Sources of Liquidity

To date, we have financed our operations primarily through the sale of equity securities and convertible debt and, to a lesser extent, through grants from governmental and other agencies. Since our inception, we have incurred significant operating losses and negative cash flows. As of September 30, 2021 and December 31, 2020, we had an accumulated deficit of $457.2 and $388.1 million, respectively.

As of September 30, ~~2020,~~2021, we had cash ~~outside the Trust Account~~and cash equivalents of ~~$1,316,314 available for working capital needs. All remaining~~$240.4 million. We believe our cash ~~held in the Trust Account are generally unavailable for the Company’s use, prior to an initial business combination,~~ and ~~is restricted for use either in a Business Combination or to redeem common stock. As of September 30, 2020, none of the amount in the Trust Account was available to be withdrawn as described above.~~

Through September 30, 2020, the Company’s liquidity needs were satisfied through receipt of $25,000 from the sale of the founder shares, advances from the Sponsor in an aggregate amount of $89,076 and the remaining net proceeds from the IPO and the sale of Private Placement Units.

~~The Company anticipates that the $1,316,314 outside of the Trust Account as of September 30, 2020,~~cash equivalents will be sufficient to ~~allow the Company to operate~~fund operations, including clinical trial expenses and capital expenditure requirements, for at least the next 12 months ~~assuming that a~~from the date of this Quarterly Report. See Note 1, “Organization and Description of Business, ~~Combination is not consummated during that time. Until consummation of its Business Combination, the Company will be using the funds not held~~” in the ~~Trust Account, and any~~notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report for additional ~~Working Capital Loans (as defined~~information regarding this assessment.

Table of Contents

In April 2020, we received loan proceeds in the ~~condensed interim financial statements) from~~amount of approximately $3.3 million under the ~~initial stockholders,~~PPP. The loan and accrued interest were forgivable after a 24-week period as long as we used the ~~Company’s officers~~loan proceeds for eligible purposes, including payroll, benefits, rent and ~~directors, or their respective affiliates, for identifying~~utilities, and ~~evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from~~maintained its payroll levels. On May 25, 2021, the ~~offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting~~Small Business Administration approved the ~~target business to acquire and structuring, negotiating and consummating the Business Combination.~~

~~The Company does not believe it will need to raise additional funds in order to meet the expenditures required for operating its business. However, if the Company’s estimates~~forgiveness of the ~~costs of undertaking in-depth due diligence and negotiating business combination is less than the actual~~outstanding amount necessary to do so, the Company may have insufficient funds available to operate its business prior to the business combination. Moreover, the Company will need to raise additional capital through loans from its Sponsor, officers, directors, or third parties. None of the ~~Sponsor, officers or directors are under any obligation to advance funds to, or to invest~~PPP loan and we recognized a gain from loan extinguishment in the ~~Company. If~~amount of $3.3 million during the ~~Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity,~~nine months ended September 30, 2021.

In March 2021, we entered into the Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of its business plan, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

~~Related Party Transactions~~

~~Founder Shares~~

On July 20, 2020, we issued 2,875,000 shares of Class B common stock to our initial stockholder, AHAC Sponsor, LLC for $25,000, or approximately $0.01 per share. The founder shares include an aggregateprovides a term loan facility of up to ~~375,000 shares subject~~$50.0 million, with a maturity date of March 1, 2025, of which $20.0 million was funded upon the closing of the Loan Agreement, and the additional $30.0 million is accessible in three tranches of $10.0 million each contingent on the achievement of certain business and clinical development milestones. Our obligations under the Loan Agreement are secured by substantially all of our assets, except for our intellectual property. The Loan Agreement contains certain customary covenants, including, but not limited to, ~~forfeiture if~~those relating to additional indebtedness, liens, asset divestitures, and affiliate transactions. We may use the ~~over-allotment option~~proceeds of borrowings under the Loan Agreement as working capital and to fund our general business requirements.

Borrowings under the Loan Agreement bear interest at a rate of 7.5% or the sum of the Wall Street Journal Prime Rate plus 4.25%, whichever is ~~not exercised by~~greater. In addition, the ~~underwriters in full.~~ lenders were granted warrants to purchase Common Stock.

As of September 30, ~~2020, 2,875,000 shares~~2021, principal of ~~common stock (the “Founder Shares”) are issued and outstanding. The over-allotment option~~$20.0 million was ~~not exercised by the underwriters during the 45-day option period; thus, these shares were forfeited accordingly as of November 1, 2020.~~

~~Promissory Note — Related Party~~

On July 1, 2020, we issued an unsecured promissory note to the sponsor, pursuant to which we may borrow up to an aggregate principal amount of $300,000 to be used for a portion of the expenses of the IPO. This loan is non-interest bearing, unsecured, and due on the earlier of (a) March 31, 2021 or (b) the date on which we complete the IPO. The loan will be repaid out of the offering proceeds not held in the Trust Account. As of September 30, 2020, we had $89,076 in borrowings outstanding under the ~~promissory note.~~

~~Administrative Service Fee~~

~~We have agreed to pay an affiliate of our sponsor a monthly fee of an aggregate of $10,000 for general~~Loan Agreement and administrative services including office space, utilities and secretarial and administrative support. This arrangement will terminate upon completion of a business combination or the liquidation of the Company. For the period July 1, 2020 through September 30, 2020, we ~~accrued $4,334 of administrative fees as a due to related party payable.~~

~~Related Party Loans~~

~~In addition,~~were in ~~order to finance transactions costs~~compliance with all covenants in ~~connection with a business combination, the sponsor, or certain of the Company’s officers, directors, or their affiliates may, but are not obligated to, loan~~all material respects. On October 13, 2021, the Company funds as may be required (“Working Capital Loans”). If the Company completes a business combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a business combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be converted into units of the post business combination entity at a price of $10.00 per unit.

~~Commitments and Contingencies~~

~~Registration Rights~~

The holders of the founder shares, placement units (including securities contained therein) and units (including securities contained therein) that may be issued upon conversion of working capital loans, and any shares of Class A common stock issuable upon the exercise of the placement warrants and any shares of Class A common stock and warrants (and underlying Class A common stock) that may be issued upon conversion of the units issued as part of the working capital loans and Class A common stock issuable upon conversion of the founder shares, will be entitled to registration rights pursuant to the registration rights agreement requiring us to register such securities for resale (in the case of the founder shares, only after conversion to our Class A common stock). The holders of the majority of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion ofborrowed an ~~initial business combination and rights to require us to register for resale such securities pursuant to Rule 415~~additional $10.0 million under the Securities Act. The registration rights agreement does not contain liquidated damages or other cash settlement provisions resulting from delays in registering our securities. The Company will bear the expenses incurred in connection with the filingLoan Agreement, and principal of ~~any such registration statements.~~

~~Underwriting Agreement~~

On September 22, 2020, the underwriters were paid an underwriting discount of two percent (2.0%) of the gross proceeds of the IPO, or $2,000,000. In addition, the underwriters are entitled to a deferred underwriting fee of three and a half percent (3.5%) of the gross proceeds of the IPO upon the completion of the Company’s initial business combination. The underwriters have agreed that up to 1% of the deferred underwriting fee may be re-directed to other FINRA member firms that have provided services in connection with the identification and consummation of a business combination, in the sole discretion of the Company; provided, that all such payments to other FINRA member firms may only be made if permitted under applicable law.

The Company may reduce the deferred underwriting fee by up to 50% based on stockholders redeeming their shares for their pro-rata amount of the proceeds in the Trust Account; provided, however, that (a) the underwriters’ maximum deferred underwriting fee reduction based on stockholder redemptions will be 50% regardless of whether stockholder redemptions exceed 50%; and (b) any sums paid to other advisors as discussed above, will be credited against the reduction of and added back to the deferred underwriting fee payable to the underwriters; and (c) under no circumstance will the deferred underwriting fee be less than 1.75% of the gross proceeds of the IPO. As of September 30, 2020, the Company accrued a deferred underwriting fee of $1,846,265.

~~Risks and Uncertainties~~

~~Management~~$30.0 million is continuing to evaluate the impact of the COVID-19 pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the our financial position, results of our operations and/or search for a target company, the specific impact is not readily determinableoutstanding as of the date of ~~these financial statements. The financial statements do not include any adjustments that might~~this Quarterly Report. As a result ~~from~~of the ~~outcome~~additional borrowing, the commencement of ~~this uncertainty.~~repayment of principal was deferred to no earlier than July 2023.

~~Off-Balance Sheet Arrangements~~

AsIncluding the additional $10.0 million borrowed, our contractual obligations under the Loan Agreement as of September 30, 2021, include cash payments related to principal and interest of $2.2 million within one year, $25.0 million within one to three years, and $10.3 million within three to five years.

Future Funding Requirements

Until such time, if ever, as we are able to successfully develop and commercialize one or more of our product candidates, we expect to continue financing our operations through the sale of equity, debt, borrowings under credit facilities or through potential collaborations with other companies, other strategic transactions or government or other grants. Adequate capital may not be available to us when needed or on acceptable terms. We do not currently have any committed external source of funds beyond the Loan Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures. Debt financing would also result in fixed payment obligations. If we are unable to raise additional funds through equity or debt financings or other strategic arrangements when needed, we may be required to delay, reduce, suspend or cease our research and development programs or any future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.

Humacyte’s principal use of cash in recent periods has been funding its operations. Humacyte’s future capital requirements, both short-term and long-term, will depend on many factors, including the progress and results of our clinical trials and preclinical development, timing and extent of spending to support development efforts, cost and timing of future commercialization activities, and the amount and timing of revenues, if any, that we receive from commercial sales.

See the section of this Quarterly Report entitled “Risk Factors” for additional risks associated with our substantial capital requirements.

Table of Contents

Cash Flows

The following table shows a summary of our cash flows for each of the periods shown below:


	Nine Months Ended September 30,
($in thousands)	2021		2020
Statement of cash flows data:
Total cash (used in)/provided by:
Operating activities	$	(59,742)	$	(40,373)
Investing activities		(175)		(255)
Financing activities		260,437		2,379
	$	200,520	$	(38,249)

Cash Flow from Operating Activities

Net cash used in operating activities of $59.7 million during the nine months ended September 30, 2021 was primarily the result of our net loss of $69.1 million to support our research and development, including clinical trial, manufacturing and regulatory costs, and general and administrative costs, $12.4 million related to payments of liabilities acquired in the Merger, and adjustments for non-cash expenses related primarily to a $9.8 million loss related to the change in the fair value of our contingent earnout liability, $7.4 million of stock-based compensation, $4.7 million of depreciation expense, $1.5 million for amortization of finance lease right-of-use assets, and $0.6 million amortization of Silicon Valley Bank debt discount, partially offset by a $3.3 million non-cash gain on PPP loan forgiveness. We also experienced a $1.0 million net favorable change in cash related to operating assets and liabilities primarily related to an increase in accrued expenses of $2.4 million, an increase in accounts payable of $0.8 million, partially offset by an increase in prepaid expenses of $2.0 million.

Net cash used in operating activities of $40.4 million during the nine months ended September 30, 2020 was primarily the result of our net loss of $50.3 million to support our research and development, including clinical trial, manufacturing and regulatory costs, and general and administrative costs, with adjustments for non-cash expenses related primarily to $4.7 million of depreciation expense, $3.5 million of stock-based compensation and $1.5 million for amortization of finance lease right-of-use assets.

Cash Flow from Investing Activities

Net cash used in investing activities during the nine months ended September 30, 2021 was $0.2 million, primarily consisting of the purchases of laboratory equipment.

Net cash used in investing activities during the nine months ended September 30, 2020 was $0.3 million, primarily consisting of the purchases of laboratory and manufacturing equipment.

Cash Flow from Financing Activities

Net cash provided by financing activities during the nine months ended September 30, 2021 was $260.4 million, consisting of $242.4 million of proceeds from the Merger and the PIPE Financing, $19.7 million of net proceeds from our loan facility with Silicon Valley Bank and $0.6 million from the exercise of stock options, partially offset by $0.9 million of transaction costs paid and principal payments of $1.3 million in connection with a finance lease obligations.

Net cash provided by financing activities during the nine months ended September 30, 2020 was $2.4 million, consisting of $3.3 million of the proceeds from our PPP loan and proceeds of $0.2 million from the exercise of stock options, partially offset by principal payments of $1.1 million in connection with a finance lease obligation.

Table of Contents

Contractual Obligations and Commitments

The following table summarizes our contractual obligations as of September 30, 2021:


			Less than 1						More than 5
($in thousands)	Total		year		1 - 3 years		3 - 5 years		years
Contractual obligations:
Finance leases	$	33,952	$	950	$	7,833	$	8,232	$	16,937
Operating leases		1,126		26		210		210		680
SVB loan payable		23,980		5,336		14,813		3,831		—
Noncancelable purchase commitments (1)		12,411		12,411		—		—		—
Total contractual obligations	$	71,469	$	18,723	$	22,856	$	12,273	$	17,617

(1)

As of September 30, 2021, we had non-cancellable purchase commitments of $12.4 million for supplies and services that are primarily for research and development. We have also entered into contracts with CROs primarily for clinical trials. These contracts generally provide for termination upon limited notice, and therefore we believe that our non-cancellable obligations under these agreements are not material.

The table above does not include potential milestone payments, license fee payments, royalties and other payments that we may be required to make under our license agreements with Duke University and Yale University and our distribution agreement with Fresenius Medical Care Holdings, Inc. These payments are not included in the preceding table as the amount and timing of such payments are unknown or uncertain at September 30, 2021. For additional information regarding these agreements and the nature of payments that could become due thereunder, see “— Business — Distribution,” and “— Business — Intellectual Property” included in the Company’s Registration Statement on Form S-1, filed with the SEC on September 17, 2021 and amended on October 22, 2021. Our contractual obligations increased materially from December 31, 2020 as a result of entering into the Loan Agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P., which provides a term loan facility of up to $50.0 million with a maturity date of March 1, 2025, of which $20.0 million was outstanding as of September 30, 2021.

On October 13, 2021, we borrowed an additional $10.0 million under the term loan facility. Including the additional $10.0 million borrowed, our contractual obligations under the Loan Agreement as of September 30, 2021 include cash payments related to principal and interest of $2.2 million within one year, $25.0 million within one to three years, and $10.3 million within three to five years.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in ~~Item 303(a)(4)(ii)~~SEC rules and regulations.

Critical Accounting Policies and Significant Judgments and Estimates

Our discussion and analysis of ~~Regulation S-K. We do not participate in transactions that create relationships with unconsolidated entities or~~our financial ~~partnerships, often referred to as variable interest entities,~~condition and results of operations are based upon our condensed consolidated financial statements, which ~~would~~ have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

~~Contractual Obligations~~

~~We do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities, other than the underwriters are entitled to a deferred fee of $1,846,265~~prepared in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that we complete a Business Combination, subject to the terms of the underwriting agreement.

~~Critical Accounting Policies~~

accordance with U.S. generally accepted accounting principles. The preparation of ~~condensed~~our financial statements ~~and related disclosures in conformity with accounting principles generally accepted in the United States of America~~ requires ~~management~~us to make estimates, assumptions and ~~assumptions~~judgments that affect the reported amounts of assets, liabilities, costs and ~~liabilities, disclosure~~expenses. We base our estimates and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates.

Other than the policies noted in Part I, Item 1, Note 2, “Summary of ~~contingent assets and liabilities at~~Significant Accounting Policies,” in our notes to the ~~date of the~~condensed consolidated financial statements ~~and income and expenses during the periods reported. Actual results could materially differ from those estimates. We~~in this Quarterly Report on Form 10-Q, there have ~~not identified any~~been no material changes to our critical accounting ~~policies.~~policies and estimates as compared to those disclosed in our audited consolidated financial statements as of and for the years ended December 31, 2020 and 2019, included in the Company’s Registration Statement on Form S-1, filed with the SEC on September 17, 2021 and amended on October 22, 2021.

Table of Contents

Recent Accounting ~~Standards~~Pronouncements

~~Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on~~See Note 2, “Summary of Significant Accounting Policies,” in our notes to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of recent accounting pronouncements applicable to our financial statements.

~~JOBS Act~~

Emerging Growth Company and Smaller Reporting Company Status

The ~~JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We qualify as~~Company is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012 (the “JOBS Act”), and ~~under~~may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies until it is no longer an emerging growth company. Section 107 of the JOBS Act ~~will be allowed to comply with new or revised accounting pronouncements based on~~provides that an emerging growth company can take advantage of the ~~effective date~~extended transition period afforded by the JOBS Act for ~~private (not publicly traded) companies. We are electing to delay~~ the ~~adoption~~implementation of new or revised accounting ~~standards,~~standards. We expect the Company to avail itself of the extended transition period and, ~~as a result, we may~~therefore, while the Company is an emerging growth company it will not ~~comply with~~be subject to new or revised accounting standards onat the ~~relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements may not be comparable~~same time that they become applicable to other public companies that ~~comply with~~are not emerging growth companies, unless it chooses to early adopt a new or revised accounting ~~pronouncements as~~standard. This may make it difficult or impossible to compare the Company’s financial results with the financial results of another public company ~~effective dates.~~that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions because of the potential differences in accounting standards used.

Additionally, ~~we are~~the Company is a “smaller reporting company” as defined in ~~the process~~Item 10(f)(1) of ~~evaluating the benefits~~Regulation S-K. Smaller reporting companies may take advantage of ~~relying on the other~~certain reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to,disclosure obligations, including, among other things, ~~(i) provide an auditor’s attestation report on our system~~providing only two years of ~~internal controls over~~audited financial statements. The Company will remain a smaller reporting ~~pursuant to Section 404, (ii) provide all~~company if (1) the market value of Common Stock held by non-affiliates is less than $250 million as of the ~~compensation disclosure that may be required~~last business day of ~~non-emerging growth public companies under~~ the ~~Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by~~second fiscal quarter, or (2) the ~~PCAOB regarding mandatory audit firm rotation or a supplement to~~Company’s annual revenues in its most recent fiscal year completed before the ~~auditor’s report providing additional information about the audit~~last business day of its second fiscal quarter are less than $100 million and the ~~financial statements (auditor discussion and analysis) and (iv) disclose certain executive compensation related items such~~market value of Common Stock held by non-affiliates is less than $700 million as ~~the correlation between executive compensation and performance and comparisons~~ of the ~~CEO’s compensation to median employee compensation. These exemptions will apply for a period~~last business day of ~~five years following~~ the ~~completion of our initial public offering or until we are no longer an “emerging growth company,” whichever is earlier.~~second fiscal quarter.

Item 3. Quantitative and Qualitative Disclosures ~~about~~About Market ~~Risk.~~Risk

We are exposed to market risk in the ordinary course of business. As of September 30, 2021 and December 31, 2020, we were not subject to any material market, currency, or interest rate risk. ~~Following~~

Our primary exposure to market risk is associated with changes in interest rates related to the ~~consummation~~interest income from our cash and cash equivalents of ~~our Initial Public Offering, the net proceeds~~$240.4 million and $39.9 million as of ~~our Initial Public Offering~~September 30, 2021 and ~~the sale of the Private Placement Units are held in the Trust Account and will be invested in U.S. government treasury bills with a maturity of 185 days or less or~~December 31, 2020, respectively, which we invest in money market funds ~~meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest~~invested only in ~~direct~~obligations of the U.S. government ~~treasury obligations.~~and its agencies. Due to the short-term ~~nature~~maturities and low risk profile of ~~these investments, we believe there will be no associated~~our cash and cash equivalents, an immediate 10.0% change in interest rates would not have a material ~~exposure to interest rate risk.~~effect on our financial position or results of operations.

Item 4. Controls and ~~Procedures.~~Procedures

Changes in Internal Control Over Financial Reporting

~~Evaluation~~Prior to the Merger, AHAC made the determination that it was required to restate certain previously issued financial statements and related disclosures for the periods disclosed in its Annual Report on Form 10-K for the year ended December 31, 2020 in order to correct the accounting treatment for the Company’s warrants. The determination by AHAC was made following the publication by the SEC on April 12, 2021 of ~~Disclosure Controls~~a statement regarding the accounting and ~~Procedures~~

~~Under the supervision~~reporting considerations for warrants issued by special purpose acquisition companies entitled “Staff Statement on Accounting and ~~with the participation of our~~Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”).” In addition, AHAC's management ~~including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our~~concluded that its disclosure controls and procedures and internal control over financial reporting were not effective as of December 31, 2020, solely as a result of a material weakness in controls related to the accounting for the warrants.

Effective as of the ~~end~~closing of the ~~fiscal quarter ended~~Merger, the management of Legacy Humacyte is responsible for internal control over financial reporting and the former management of AHAC no longer participates in financial reporting. Our assessment is that, post merger, we have a sufficiently staffed and technically experienced finance and accounting team to address the financial reporting requirements of a public company. At that point, because the conditions causing the material weakness no longer existed, and are not expected to exist, we determined the material weakness did not exist in internal control over financial reporting as of September 30, 2020, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that during the period covered by this report, our disclosure controls and procedures2021.

Table of Contents

There were ~~effective.~~

Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~Changes in Internal Control over Financial Reporting~~

~~There was~~ no ~~change~~changes in our internal control over financial reporting ~~that occurred~~(as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the ~~fiscal quarter~~three months ended September 30, ~~2020 covered by this Quarterly Report on Form 10-Q~~2021 that ~~has~~have materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.

Evaluation of Disclosure Controls and Procedures

20Our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2021. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2021.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal ~~Proceedings.~~Proceedings

~~None.~~

Item 1A. Risk ~~Factors.~~Factors

Our business is subject to substantial risks and uncertainties. As a result of the ~~date~~closing of the Merger, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 no longer apply. Following the Merger, factors that could cause our actual results to differ materially from those in this Quarterly Report ~~there~~include the risks described in the section entitled “Risk Factors” of our Registration Statement on Form S-1, filed with the SEC on September 17, 2021 and amended on October 22, 2021. There have been no material changes to ~~the~~our previously disclosed risk factors disclosed in our final prospectus filed with the SEC on September 18, 2020, except we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.factors.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds ~~from Registered Securities~~

The following list sets forth information regarding all unregistered securities sold by us during the quarter ended September 30, 2021:

(1)

On August 26, 2021, concurrently with the closing of the Business Combination, we issued 17,500,000 shares of Common Stock for an aggregate purchase price of $175.0 million to certain qualified institutional buyers and accredited investors, at a price of $10.00 per share.

(2)

Upon the closing of the Business Combination, unvested options to purchase an aggregate of 8,949,680 shares of Legacy Humacyte common stock at exercise prices of $2.226 to $2.699 per share under Humacyte’s 2015 Omnibus Incentive Plan, as amended, and Humacyte’s 2005 Stock Option Plan, as amended, were automatically and without any required action on the part of any holder or beneficiary thereof, assumed by us and converted into options to purchase an aggregate of 2,350,003 shares of Common Stock at exercise prices of $8.48 to $10.28.

(3)

On October 13, 2021, we issued warrants to purchase an aggregate of up to 123,302 shares of Common Stock to Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P. at an exercise price of $10.28 per share.

On September 22, 2020, we consummated our initial public offering (the “IPO”) of 10,000,000 units (the “Units”). Each Unit consists of one share of Class A common stock, par value $0.0001 per share (“Class A Common Stock”) and one-half of one redeemable warrant (each whole warrant, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one share of Class A Common Stock for $11.50 per share. The Units were sold at a price of $10.00 per Unit, generating gross proceeds to us of $100,000,000. We granted the underwriters in the IPO, a 45-day option to purchase up to 1,500,000 additional Units solely to cover over-allotments, if any. Oppenheimer & Co. Inc. acted as the sole book running manager and Northland Securities, Inc. acted as the co-managerNone of the ~~IPO. The securities sold in the IPO were registered~~foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe each of these transactions was exempt from registration under the Securities Act ~~on registration statements on Form S-1 No. 333-240374. The SEC declared the registration statement effective on September 17, 2020.~~

~~On September 22, 2020, simultaneously with the consummation~~ of ~~the IPO, we completed the private sale~~1933, as amended (the ~~“Private Placement”~~“Securities Act”) of an aggregate of 355,000 Units (the “Private Placement Units”) to AHAC Sponsor LLC, Oppenheimer & Co. Inc. and Northland Securities, Inc., generating gross proceeds to us of $3,550,000. Such securities were issued pursuant to the exemption from registration contained in reliance on Section 4(a)(2) of the Securities ~~Act.~~

~~A total of $100,000,000, comprised of $98,000,000~~Act (and Regulation D promulgated thereunder) as transactions by an issuer not involving any public offering or Rule 701 promulgated under Section 3(b) of the ~~proceeds from the IPO~~Securities Act as transactions by an issuer under benefit plans and ~~$2,000,000~~contracts relating to compensation as provided under Rule 701. The recipients of the ~~proceeds~~securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed on the share certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of ~~the Private Placement Units, was placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee.~~these securities were made without any general solicitation or advertising.

~~We paid a total of $4,175,978 of transaction costs consisting of $2,000,000 of underwriting fee, $1,846,265 of deferred underwriting fee and $329,713 of other offering costs.~~

~~For a description of the use of the proceeds generated in our IPO, see Part I, Item 2 of this Form 10-Q.~~

Item 3. Defaults Upon Senior ~~Securities.~~

Securities

None.

Item 4. Mine Safety ~~Disclosures.~~Disclosures

None.

~~Not applicable.~~

Item 5. Other ~~Information.~~

Information

None.

Table of Contents

Item 6. ~~Exhibits.~~

Exhibits

The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.

~~Exhibit~~ ~~Number~~		~~Description~~
Exhibit Number		Description
~~1.1~~ 3.1		~~Underwriting Agreement, dated September 17, 2020, by and between the Company and Oppenheimer & Co. Inc., as representative of the several underwriters. (1)~~

~~3.1~~		Second Amended and Restated Certificate of ~~Incorporation. (1)~~Incorporation of Humacyte, Inc. (incorporated by reference to Exhibit 3.1 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

~~4.1~~ 3.2		~~Warrant~~By Laws of Humacyte, Inc. (incorporated by reference to Exhibit 3.2 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

4.1		Form of Subscription Agreement ~~dated September 17, 2020,~~(incorporated by reference to Exhibit 10.3 to Humacyte, Inc.’s Registration Statement on S-4/A, filed with the SEC on August 2, 2021).

4.2		Form of Investor Rights and Lock-up Agreement (incorporated by reference to Exhibit 4.3 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

4.3		Form of Lock-up Agreement (incorporated by reference to Exhibit 10.1 to Humacyte, Inc.’s Registration Statement on S-4/A, filed with the SEC on August 2, 2021).

10.1		Humacyte, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

10.1.1		Form of Stock Option Agreement under Humacyte, Inc. 2021 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.4.1 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

10.2		Humacyte, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.5 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

10.3		Humacyte, Inc. Annual Bonus Plan (incorporated by reference to Exhibit 10.8 to Humacyte, Inc.’s Current Report on Form 8-K, filed with the SEC on August 27, 2021).

10.4		Form of Indemnity Agreement by and between ~~the Company~~Humacyte, Inc. and ~~Continental Stock Transfer & Trust Company, as warrant agent. (1)~~

~~10.1~~		~~Letter Agreement, dated September 17, 2020, by and among the Company, its officers,~~each of its directors and executive officers (incorporated by reference to Exhibit 10.23 to Humacyte, Inc.’s Registration Statement on S-4/A, filed with the ~~Sponsor. (1)~~SEC on July 1, 2021).

~~10.2~~ 31.1*		~~Investment Management Trust Agreement, dated September 17, 2020, by and between the Company and Continental Stock Transfer & Trust Company, as trustee. (1)~~

~~10.3~~		~~Registration Rights Agreement, dated September 17, 2020, by and among the Company and certain security holders. (1)~~

~~10.4~~		~~Administrative Support Agreement, dated September 17, 2020, by and between the Company and Constellation Alpha Holdings LLC. (1)~~

~~10.5~~		~~Unit Subscription Agreement, dated September 17, 2020, by and between the Company and the Sponsor. (1)~~

~~10.6~~		~~Unit Subscription Agreement, dated September 17, 2020, by and between the Company and Oppenheimer & Co. Inc. (1)~~

~~10.7~~		~~Unit Subscription Agreement, dated September 17, 2020, by and between the Company and Northland Securities, Inc. (1)~~

~~31.1~~		Certification of Chief Executive Officer ~~Pursuant~~pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as ~~Adopted Pursuant~~adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~31.2~~ 31.2*		Certification of Chief Financial Officer ~~Pursuant~~pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as ~~Adopted Pursuant~~adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

~~32.1~~ 32.1**		Certification of Chief Executive Officer ~~Pursuant~~pursuant to 18 U.S.C. Section 1350, as ~~Adopted Pursuant~~adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~32.2~~ 32.2**		Certification of Chief Financial Officer ~~Pursuant~~pursuant to 18 U.S.C. Section 1350, as ~~Adopted Pursuant~~adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

~~101.INS~~		~~XBRL Instance Document~~

~~101.SCH~~		~~XBRL Taxonomy Extension Schema Document~~

~~101.CAL~~		~~XBRL Taxonomy Extension Calculation Linkbase Document~~

~~101.DEF~~		~~XBRL Taxonomy Extension Definition Linkbase Document~~

~~101.LAB~~		~~XBRL Taxonomy Extension Label Linkbase Document~~

~~101.PRE~~		~~XBRL Taxonomy Extension Presentation Linkbase Document~~

Table of Contents

101*

~~(1)~~	~~Previously filed as an exhibit to our Current~~ The following materials from Humacyte, Inc.’s Quarterly Report on Form ~~8-K filed on~~10-Q for the quarter ended September ~~22, 2020~~30, 2021, formatted in Inline XBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Operations and ~~incorporated by reference herein.~~Comprehensive Loss, (iii) Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited), (v) Notes to Condensed Consolidated Financial Statements, and (vi) Cover Page.

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Filed herewith.

** This exhibit is being furnished rather than filed, and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 12th day of November, ~~2020.~~2021.

	~~Alpha Healthcare Acquisition Corp.~~
				HUMACYTE, INC.

Date: November 12, 2021	By:	/s/ ~~Rajiv S. Shukla~~Laura E. Niklason, M.D., Ph.D.
		Name:	~~Rajiv S. Shukla~~ Laura E. Niklason, M.D., Ph.D.
		Title:	President and Chief Executive Officer

	By:	/s/ Dale A. Sander
		Name:	Dale A. Sander
		Title:	Chief Financial Officer, Chief Corporate Development Officer and Treasurer

~~Delaware~~ incorporation or organization)	~~001-39532~~	~~85-1763759~~ Identification Number)
Delaware (State or other jurisdiction of incorporation or organization)	85-1763759 (I.R.S. Employer Identification Number)

2525 East North Carolina Highway 54 Durham, NC (Address of ~~incorporation)~~principal executive offices)	27713 (~~Commission~~ ~~File Number)~~	~~(IRS Employer~~ ~~Identification No.)~~Zip code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered

~~Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant~~	~~AHACU~~	~~The Nasdaq Stock Market LLC~~
~~Class A~~ Common Stock, par value $0.0001 per share	~~AHAC~~ HUMA	The Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of ~~Class A~~ Common Stock at an exercise price of $11.50	~~AHACW~~ HUMAW	The Nasdaq Stock Market LLC


Large accelerated filer☐	Accelerated filer☐
Non-accelerated filer☒	Smaller reporting company ☒
	Emerging growth company ☐☒

			~~Page No.~~
		Page No.

	PART I.I – FINANCIAL INFORMATION

Item 1.	~~Unaudited Condensed~~ Financial Statements		1

	~~Unaudited~~ Condensed Consolidated Balance ~~Sheet as of September 30, 2020~~Sheets (unaudited)		1

	~~Unaudited~~ Condensed Consolidated Statements of Operations ~~for the period from July 1, 2020 (Inception) through September 30, 2020~~and Comprehensive Loss		2

	~~Unaudited~~ Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity ~~for the period from July 1, 2020 (Inception) through September 30, 2020~~(Deficit) (unaudited)		3

	~~Unaudited~~ Condensed Consolidated Statements of Cash Flows ~~for the period from July 1, 2020 (Inception) through September 30, 2020~~(unaudited)		4

	Notes to ~~Unaudited~~ Condensed Consolidated Financial Statements (unaudited)		5

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15 28

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		20 38

Item 4.	Controls and Procedures		20 38

	PART ~~II.~~II – OTHER INFORMATION

Item 1.	Legal Proceedings		21 40

Item 1A.	Risk Factors		21 40

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds ~~from Registered Securities~~		21 40

Item 3.	Defaults Upon Senior Securities		21 40

Item 4.	Mine Safety Disclosures		21 40

Item 5.	Other Information		21 40

Item 6.	Exhibits		22 41

SIGNATURES			23 43


	September 30,		December 31,
	2021		2020

ASSETS
Current assets
Cash and cash equivalents	$	240,449	$	39,929
Accounts receivable		240		113
Prepaid expenses		3,490		1,407
Total current assets		244,179		41,449

Finance lease right-of-use assets, net		21,947		23,492
Operating lease right-of-use assets, net		738		769
Property and equipment, net		36,499		40,978
Total assets	$	303,363	$	106,688

	September 30,		December 31,
	2021		2020
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable	$	5,830	$	2,274
Accrued expenses		9,422		4,592
SVB loan payable, current portion		3,889		—
Finance lease obligation, current portion		1,915		1,729
Deferred payroll tax, current portion		145		145
Operating lease obligation, current portion		44		42
PPP loan payable, current portion		—		2,451
Total current liabilities		21,245		11,233

Contingent earnout liability		169,200		—
Finance lease obligation, net of current portion		21,627		23,090
SVB loan payable, net of current portion		14,038		—
Operating lease obligation, net of current portion		693		727
Common stock warrant liabilities		555		—
Deferred payroll tax, net of current portion		144		144
PPP loan payable, net of current portion		—		822
Total liabilities		227,502		36,016

Commitments and contingencies (Note 11)
Redeemable convertible preferred stock (Series A, B, C and D) $0.001 par value, 0 and 69,613,565 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 0 and 69,613,562 shares outstanding as of September 30, 2021 and December 31, 2020, respectively; liquidation preference of $0 and $435,579 as of September 30, 2021 and December 31, 2020, respectively.		—		420,989

Stockholders' equity (deficit)
Preferred stock, $0.0001 par value; 20,000,000 and 0 shares designated as of September 30, 2021 and December 31, 2020; 0 shares issued and outstanding as of September 30, 2021 and December 31, 2020		—		—
Common stock, $0.0001 and $0.0001 par value as of September 30, 2021 and December 31, 2020, respectively; 250,000,000 and 340,216,780 shares authorized as of September 30, 2021 and December 31, 2020, respectively; 103,003,384 and 5,822,396 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively.		10		1
Additional paid-in capital		533,009		37,778
Accumulated deficit		(457,158)		(388,096)
Total stockholders' equity (deficit)		75,861		(350,317)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	$	303,363	$	106,688


	For the Three Months Ended September 30,				For the Nine Months Ended September 30,
	2021		2020		2021			2020

Grant revenue	$	241	$	914	$	1,086	$	1,367

Operating expenses:
Research and development (includes related party expenses of $2 and $149 for the three months ended September 30, 2021 and 2020 and $168 and $462 for the nine months ended September 30, 2021 and 2020)		15,386		14,692		45,091		40,879
General and administrative		5,398		3,435		15,576		9,416
Total operating expenses		20,784		18,127		60,667		50,295
Loss from operations		(20,543)		(17,213)		(59,581)		(48,928)

Other expenses, net:
Interest income		3		2		6		277
Change in fair value of contingent earnout liability		(9,768)		-		(9,768)		—
Interest expense		(1,204)		(549)		(2,952)		(1,661)
Transaction costs expensed		(49)		—		(49)		—
Change in fair value of common stock warrant liabilities		(2)		—		(2)		—
Gain on PPP loan forgiveness		—		—		3,284		—
Total other expenses, net		(11,020)		(547)		(9,481)		(1,384)
Net loss and comprehensive loss	$	(31,563)	$	(17,760)	$	(69,062)	$	(50,312)

Net loss per share attributable to common stockholders, basic and diluted	$	(0.72)	$	(3.07)	$	(3.69)	$	(8.74)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		43,950,856		5,788,130		18,728,471		5,755,418


	Redeemable Convertible
	Preferred Stock			Common Stock			Additional		Accumulated		Total Stockholders'
	Shares	Amount		Shares	Amount		Paid-in Capital		Deficit		(Deficit) Equity
Balance as of December 31, 2020	69,613,562	$	420,989	5,822,396	$	1	$	37,778	$	(388,096)	$	(350,317)
Proceeds from the exercise of stock options	—		—	116,149		—		206		—		206
Stock-based compensation	—		—	—		—		2,528		—		2,528
Issuance of warrants in conjunction with debt	—		—	—		—		2,360		—		2,360
Net loss	—		—	—		—		—		(20,301)		(20,301)
Balance as of March 31, 2021	69,613,562	$	420,989	5,938,545	$	1	$	42,872	$	(408,397)	$	(365,524)
Proceeds from the exercise of stock options	—		—	5,204		—		30		—		30
Stock-based compensation	—		—	—		—		2,930		—		2,930
Net loss	—		—	—		—		—		(17,198)		(17,198)
Balance as of June 30, 2021	69,613,562	$	420,989	5,943,749	$	1	$	45,832	$	(425,595)	$	(379,762)
Conversion of redeemable convertible preferred stock into common stock in connection with the Merger and related PIPE financing	(69,613,562)		(420,989)	69,613,562		7		420,982		—		420,989
The merger and related PIPE financing, net of transaction costs and acquired liabilities	—		—	27,346,449		2		209,478		—		209,480
Public warrants assumed upon the merger, net of transaction costs	—		—	—		—		13,912		—		13,912
Contingent earnout liability recognized upon closing of the reverse recapitalization	—		—	—		—		(159,432)		—		(159,432)
Proceeds from the exercise of stock options	—		—	99,624		—		360		—		360
Stock-based compensation	—		—	—		—		1,877		—		1,877
Net loss	—		—	—		—		—		(31,563)		(31,563)
Balance as of September 30, 2021	—	$	—	103,003,384	$	10	$	533,009	$	(457,158)	$	75,861

Assets
Cash	$	1,316,314
Prepaid assets		30,670
Total current assets		1,346,984
Marketable Securities held in Trust Account		99,977,823
Total Assets	$	101,324,807

Liabilities and Stockholders’ Equity
Accounts payable	$	27,062
Due to related party		4,334
Promissory note – related party		89,076
Total current liabilities		120,472
Deferred underwriters’ discount payable		1,846,265
Total liabilities		1,966,737

Commitments

Class A common stock subject to possible redemption, 9,435,806 shares at redemption value		94,358,060

Stockholders’ Equity:
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding		—
Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 919,194 shares issued and outstanding (excluding 9,435,806 shares subject to possible redemption)		92
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 2,875,000 shares issued and outstanding ⁽¹⁾		288
Additional paid-in capital		5,040,582
Accumulated deficit		(40,952	)
Total stockholders’ equity		5,000,010

Total Liabilities and Stockholders’ Equity	$	101,324,807

	For the period from July 1, 2020 (Inception) to September 30, 2020
Formation and operating costs	$	18,775
Loss from operations		(18,775	)

Other Income/(Expense)
Unrealized loss on marketable securities held in Trust Account		(22,177	)
Total other income/(expense)		(22,177	)

Net loss	$	(40,952	)

Weighted average shares outstanding, basic and diluted. ⁽¹⁾		2,888,352
Basic and diluted net loss per common share. ⁽²⁾	$	(0.01	)

	Common Stock										Additional						Total
	Class A						Class B				Paid-In			Accumulated			Stockholders’
	Shares			Amount			Shares ⁽¹⁾		Amount		Capital			Deficit			Equity
Balance as of July 1, 2020 (inception)		—		$	—			—	$	—	$	—		$	—		$	—
Class B common stock issued to Sponsor		—			—			2,875,000		288		24,712			—			25,000
Sale of Units in Initial Public Offering		10,000,000			1,000			—		—		99,999,000			—			100,000,000
Sale of Private Placement Units		355,000			36			—		—		3,549,964			—			3,550,000
Underwriting fee		—			—			—		—		(2,000,000	)		—			(2,000,000	)
Deferred underwriting fee		—			—			—		—		(1,846,265	)		—			(1,846,265	)
Offering costs charged to the stockholders’ equity		—			—			—		—		(329,713	)		—			(329,713	)
Change in Class A common stock subject to possible redemption		(9,435,806	)		(944	)		—		—		(94,357,116	)		—			(94,358,060	)
Net loss		—			—			—		—		—			(40,952	)		(40,952	)
Balance as of September 30, 2020 (Unaudited)		919,194		$	92			2,875,000	$	288	$	5,040,582		$	(40,952	)	$	5,000,010

	~~For the period~~ ~~from July 1, 2020~~ ~~(Inception) to~~ ~~September 30, 2020~~
~~Cash Flows from Operating Activities:~~
~~Net loss~~	$	~~(40,952~~	)
~~Adjustments to reconcile net loss to net cash used in operating activities: Unrealized loss on marketable securities held in trust~~		~~22,177~~
~~Changes in current assets and current liabilities:~~
~~Prepaid assets~~		~~(30,670~~	)
~~Due to related party~~		~~4,334~~
~~Accounts payable~~		~~27,062~~
~~Net cash used in operating activities~~		~~(18,049~~	)

~~Cash Flows from Investing Activities:~~
~~Investment of cash into trust account~~		~~(100,000,000~~	)
~~Net cash used in investing activities~~		~~(100,000,000~~	)

~~Cash Flows from Financing Activities:~~
~~Proceeds from Initial Public Offering, net of underwriters’ fees~~		~~98,000,000~~
~~Proceeds from private placement~~		~~3,550,000~~
~~Proceeds from issuance of founder shares~~		~~25,000~~
~~Proceeds from issuance of promissory note to related party~~		~~89,076~~
~~Payments of offering costs~~		~~(329,713~~	)
~~Net cash provided by financing activities~~		~~101,334,363~~

~~Net Change in Cash~~		~~1,316,314~~
~~Cash - Beginning~~		-
~~Cash - Ending~~	$	~~1,316,314~~

~~Supplemental Disclosure of Non-cash Financing Activities:~~
~~Initial value of Class A common stock subject to possible redemption~~	$	~~94,394,110~~
~~Change in value of Class A common stock subject to possible redemption~~	$	~~(36,050~~	)
~~Deferred underwriters’ discount payable charged to additional paid-in capital~~	$	~~1,846,265~~


	Revenue								Accounts Receivable
	Three Months Ended September 30,				Nine Months Ended September 30,				September 30,		December 31,
	2021		2020		2021		2020		2021		2020
Grant A	—		—		—		—		—		—
Grant B	—		0	%	—		11	%	—		—
Grant C	100	%	68	%	100	%	65	%	100	%	100	%
Grant D	—		30	%	—		20	%	—		—
Total	100	%	98	%	100	%	96	%	100	%	100	%

			September 30,
Description	Level		2020
Assets:
Marketable securities held in Trust Account		1	$	99,977,823